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ChaIrMaN’S STaTEMENT
Once again 007 proved to be another significant 
year of further development for the Irish Medicines 
Board (IMB) in relation to the organisation’s primary 
objective of safeguarding public health. The breadth 
of our remit is extensive and continues to expand as 
new and important areas of regulatory policy come 
under our responsibility.
The IMB’s core focus is to safeguard and enhance 
public and animal health through the regulation of 
human and veterinary medical products and medical 
devices on the Irish market. From a strategic planning 
position, this focus underpinned all our activities. One 
of the notable highlights in this regard took place 
during the year when we improved our facilities to 
assist direct communication with the IMB on potential 
adverse events. The IMB developed a sophisticated 
online reporting mechanism which facilitates 
healthcare professionals and members of the public 
to report any suspected adverse reactions or quality 
defects associated with medicines or medical devices 
directly to us. It is available on our redesigned website 
and our hope is that this new facility will further 
enhance our ability to monitor the safety of all medicinal 
products and medical devices on the Irish market.
The year under review witnessed the IMB 
undertaking a demanding programme of work 
across all departments. Against this background  
it is a pleasure to report that we increased outputs 
across all departments while achieving consistently 
high standards of quality throughout the period.
Our work involves the assessment and monitoring 
of some 6,000 human medicines, ,00 veterinary 
medicines and over half a million medical devices  
on the Irish market. Our participation in a range of 
international and European groups is critical to our 
working in terms of having the fullest of available 
knowledge on all matters of relevance to products. 
We are significant participants in the European 
Medicines Agency (EMEA) and its working groups. 
Our Chief Executive, Mr. Pat O’Mahony, was elected 
Chairman of the Management Board of the EMEA  
in July, for a three-year term. We also participate  
in The World Health Organisation (WHO) in relation  
to monitoring medicines by supplying information  
on adverse reactions that occur in Ireland and 
assessing global safety information that can be  
of value to our fundamental role of protecting Irish 
consumers. We continue to consult closely with  
our EU counterparts and the US Food and Drug 
Administration (FDA), in sharing intelligence and 
information for mutual benefit.
Mr. Pat O’Mahony, Chairman
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During 007, the number of enforcement cases 
initiated by the IMB rose substantially to some 
,400, almost tripling the 469 in 006. This increase 
can be attributed to the continued co-operation  
with the Custom and Excise offices and An Garda 
Síochana, and increased levels of communication 
and intelligence-sharing with our international and 
European counterparts. There is no doubt that the 
increase in online purchasing of medicines and 
counterfeit medicines is a growing area and an 
issue for regulatory agencies throughout Europe. 
The IMB plays an active role in helping to protect 
consumers in this regard through its extensive 
activities both nationally and internationally.
A highlight of 007 was the IMB’s hosting of the 
international summit of heads of medicines regulatory 
bodies in December. This was the second time that 
this international meeting had taken place, with the 
inaugural event hosted by the FDA in Washington in 
006. It was a significant development for the IMB 
that Ireland played host to such an important forum. 
It involved over 0 countries including Australia, 
Canada, Germany, Singapore, UK and USA discussing 
and formulating approaches to important global 
issues such as counterfeit medicines and the 
regulation of clinical trials. The development of more 
streamlined links between agencies worldwide was 
also progressed.
During the year, our Board members and staff 
contributed to various working groups and sub-
committees both at home and internationally.  
I would like to thank all individuals who gave up their 
time and expertise. It is very much appreciated.
I would also like to acknowledge the role of the 
many independent experts who have worked 
closely with the IMB this year and express my 
appreciation to them. They contribute enormously 
to our committees and give us their expert insights 
which assist us in formulating our opinions. These 
committees provide the IMB with the highest 
calibre of experience and knowledge across a wide 
range of disciplines allowing the IMB to fulfil its  
role as the protector of public and animal health  
in Ireland.
We acknowledge the continued support of the 
Minister for Health and Children, the Minister for 
Agriculture and Food and their staff. Their continued 
co-operation with the IMB has contributed 
immensely to the organisation and indeed will 
continue to contribute to its productive operation.
I would like to take this opportunity to thank the 
Chief Executive, the Management Team and all the 
staff of the IMB for their exceptional work, enthusiasm 
and dedication in 007.
The IMB’s role continues to expand bringing with  
it new challenges for us to meet while maintaining 
the highest standards of service. We look forward 
to the year ahead with the assurance that we are 
delivering excellence in our field while always 
keeping to our core focus of protecting public  
and animal health.
Pat O’Mahony 
Chairman
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BOard MEMBErS
The Board of the IMB was appointed on st December 005 by the Minister for Health and Children,  
Ms. Mary Harney in accordance with the powers conferred on her by subsection  of section 7 of the  
Irish Medicines Board Act, 995 for the period ending st December 00.
The Board members are:
Mr. Pat O’Mahony (Chairman)
Prof. Brendan Buckley
Mr. Pat Brangan
Mr. Wilfred Higgins
Ms. Ingrid Hook
Mr. Brendan McLaughlin
Ms. Cicely Roche
Ms. Maureen Windle
Back row – (l-r): Brendan Buckley, Pat Brangan, Maureen Windle, Brendan McLaughlin. 
Front row – (l-r): Cicely roche, Ingrid hook, Pat O’Mahony (Chairman), Wilf higgins.
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ChIEF ExECuTIvE’S rEPOrT
OVERVIEW OF 007
I am pleased to report that 007 was another 
successful year for the Irish Medicines Board with 
sustained achievement in meeting the organisation’s 
mission to protect and enhance public and animal 
health through the regulation of medicines, medical 
devices and healthcare products. Any public health 
issues within our remit which emerged during  
the year were handled efficiently and successfully 
with the protection of public health at the core of  
all our activities.
As we strove to continuously improve efficiencies 
and standards across the organisation whilst 
amalgamating new areas of responsibility, the 
implementation and management of change 
continued to be a key driver within the IMB.  
As a part of this ongoing organisational process  
we instigated change programmes in the Medical 
Devices and Veterinary Medicines areas. We also 
significantly enhanced the application of our quality 
management system and successfully managed  
the affairs of the IMB in line with our statutory 
obligation that income at least meets costs.
Ireland is an important global location for the 
pharmaceutical/biopharmaceutical and medical 
devices industries and products manufactured in 
Ireland are exported worldwide. Ireland is now the 
largest exporter of pharmaceuticals in the world. 
Over 6,000 human medicinal products and over 
,000 veterinary medicinal products are authorised 
by the IMB for use in this country at present. The 
IMB’s regulation of the manufacture, marketing  
and distribution of medicinal products plays a  
very significant role in ensuring that appropriate 
standards are maintained in this sector.
HUMAn MEDICInES
Our focus on the safety, quality and efficacy of human 
medicines extends throughout the full lifecycle of  
all products: from the provision of scientific advice, 
approval of clinical trials, through to the assessment 
of applications for granting, variation and renewal of 
marketing authorisations. A key focus in this area is 
post-marketing surveillance, which encompasses 
pharmacovigilance, investigating reports of quality 
defects and a programme of product sampling and 
analysis. At all stages, patient safety remains at the 
forefront of the IMB’s focus. A wide range of safety 
Mr. Pat O’Mahony, Chief Executive
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actions were implemented during the year across  
a variety of medicines. notably, oral preparations  
of nimesulide were suspended in May and a full 
recall from the market was initiated as the IMB 
concluded that the products could no longer be 
considered safe under normal conditions of use. 
These products remain suspended at year end  
and a European-wide safety review is ongoing.
Output of applications matched input. During the 
year, the Human Medicines Department processed 
4,50 variations to product authorisations, ,08 
new product applications and ,0 renewals to 
product authorisations.
aPPLICaTION INPuT aNd OuTPuT OvErvIEW
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
18,000
20,000
2007200620052004
Total Input
Total Output
COMPLIAnCE
The IMB’s Compliance Department continued to 
carry out Good Manufacturing Practice inspections 
on the very substantial number of manufacturing 
sites operating in Ireland. It also contributed 
significantly to inspections of foreign sites on our 
own behalf, or on behalf of the European Union. 
Good Distribution Practices inspections were 
conducted on the supply chain while tissues and 
cells and blood establishment sites were also 
inspected. Licensing and export certification activities 
relating to Irish sites were carried out. Good Clinical 
Practice and Pharmacovigilance inspections were 
carried out as was a pilot programme of inspection 
of marketing authorisation holders.
During 007, a total of ,97 cases involving 
breaches of medicinal product legislation were 
initiated. The IMB seized 88,79 tablets, 06,44 
capsules, .5 litres of liquids and 40 kg of creams 
containing a variety of active substances. Market 
surveillance programmes, encompassing 
investigation of quality defects and recalls, and 
sampling and analysis, were operated. These 
included 88 human medicines recalls and nine 
veterinary medicines recalls from the market. 
Where appropriate, the implementation of follow-up  
corrective and preventative actions was overseen.  
A total of 469 medicinal products were sampled  
for analytical testing and/or checks on labelling  
and packaging compliance.
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MEDICAL DEVICES
Activity in the medical devices area continues  
to be a significant part of the work of the IMB. 
During 007, a total of 6 medical devices were 
registered, including 9 in-vitro diagnostic medical 
devices and  general medical devices. This  
area of our work continues to expand and provisions 
have been made to ensure the effective management 
of this growth through the restructuring of the 
department during 007. The IMB is dependent  
on the availability of financial resources from the 
Department of Health and Children to fund this area 
of activity and continue to advocate for additional 
Irish Medicines Board Annual Report 2007
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resources. Any public health issues relating to 
medical devices arising during the year were 
handled effectively and efficiently.
NuMBEr OF COMPLIaNCE CaSES OPENEd
0
50
100
150
200
28
75
189 189
2004 2005 2006 2007
VETERInARy MEDICInES
Animal health and welfare is of critical importance  
to the Irish economy and its reputation in relation  
to producing quality produce. The food industry  
is a very important sector in the Irish economy  
with exports of €8.6 billion recorded in 007.  
The regulation of veterinary medicines plays a 
significant part in assisting the prevention and 
treatment of disease, in enhancing animal welfare 
and in ensuring the safety of foods of animal origin. 
In 007 the IMB implemented a change programme 
in our Veterinary Medicines Department to enable 
us to better deliver on our mission.
A record number of applications for authorisation  
of veterinary medicinal products were approved by 
the IMB in 007, and despite Ireland being one of 
the smaller European Union countries we played  
a leading role acting as reference member state/
rapporteur in the centralised, mutual recognition  
and decentralised procedures. During the year, the 
department conducted a review of the distribution 
of veterinary vaccines which will form the basis of 
IMB policy henceforth. Any pharmacovigilance and 
public health issues relating to veterinary medicines 
arising during the year were handled efficiently and 
effectively.
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FInAnCE AnD  
CORPORATE AFFAIRS
In line with increased activity within the organisation 
in 007, the Finance and Corporate Affairs Department 
expanded its output across its various activities. 
This department was responsible for the building 
renovation project which was substantially completed 
by year end. The Human Resources function had  
a busy year with an increase in recruitment and 
training provision. The internal financial audit function 
conducted reviews of systems and reported directly 
to the audit committee of the Board, in compliance 
with good corporate governance requirements.
IT AnD CHAnGE 
MAnAGEMEnT
The IMB’s progressive programme of change, 
involving both an upgrade of our information 
technology and a programme of organisational 
change, reached some major milestones in 007. 
Development continued in our IT systems with  
the launch of a new enhanced website which  
has been well received and which we hope will  
be seen as the definitive online information source 
relating to medicines and medical devices in Ireland. 
The new site includes a facility for online reporting 
of suspected adverse reactions relating to human 
medicines as well as quality defects. While only 
launched towards the later half of the year, it recorded 
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extensive usage by year end. Online reporting 
makes it easier for healthcare professionals and  
the public to report issues to the IMB in an efficient 
and convenient way. Stakeholders may subscribe 
for alerts from the website by email or text 
messaging. Another important advance in 007  
was the implementation of electronic reporting  
of details of adverse reactions to the EMEA.
The department also provided increased output 
during the year by way of staff training and IT 
support as required by the organisation.
IMPLEMEnTATIOn OF  
THE nEW MEDICInES 
LEGISLATIOn AnD QMS
A series of revised regulations on human medicines 
were enacted by the Department of Health and 
Children in 007 and the IMB was fully prepared for 
the provisions of this new legislation. This was due  
to the carrying out of a significant programme to 
prepare for the implementation of revised medicines 
legislation since 005. The Department of Agriculture, 
Fisheries and Food updated the Animal Remedies 
Regulations on two occasions during 007 and the 
IMB fully implemented any relevant changes.
 
Irish Medicines Board Annual Report 2007
0
During 007, we made significant progress in the 
implementation of an IMB-wide quality system 
which brings major benefits to efficient workings  
of the organisation.
THE EUROPEAn MEDICInES 
REGULATORy SySTEM AnD 
InTERnATIOnAL AFFAIRS
In 007, the IMB continued to participate actively in 
the European medicines regulatory system through 
its involvement in EU committees and working 
parties. We continued to contribute at EMEA level 
and in June 007, the Management Board of EMEA 
elected me as its chairman, for a three year term. 
This is a significant honour and I look forward to 
assisting in the leadership and development of  
the European regulatory system. The IMB also 
continued to contribute very actively at the Heads  
of Medicines Agencies (HMA) level, providing part 
of the Permanent Secretariat to the HMA as well  
as co-chair and technical support to the process  
of quality improvement of the European network 
known as Benchmarking of European Medicines 
Agencies (BEMA). We were also engaged in the 
assessment of centralised applications for human 
and veterinary medicinal products as rapporteur and 
as reference member state in the mutual recognition 
and decentralised procedures. The IMB was the lead 
agency in Europe on the veterinary medicines side.
We continued to meet all timelines in all these 
procedures in 007.
The IMB also continued to represent Ireland at the 
European Pharmacopoeia, where Dr. Mike Morris, 
Senior Scientific Advisor, continued to mid-year  
in the role of President of the Pharmacopoeia 
Commission. During 007, Dr. Morris delivered on  
a range of significant technical projects for the IMB.
Information technology continues to be an important 
topic on the EU agenda as it works to facilitate better 
access of patients to information on medicines  
and swift, accurate and efficient sharing of relevant 
information between regulatory authorities 
throughout Europe. During 007, the IMB’s Information 
Technology (IT) department was actively involved in 
EU IT implementation activities.
In november 006, the US FDA, as part of its 
centenary celebrations, hosted an international 
summit of regulatory agencies in Washington.  
In 007, the IMB took the initiative to convene a 
second international summit in Dublin. This summit 
was well attended by agency heads from around 
the globe. A number of important topics were 
discussed during the meeting ranging from the 
threat posed to patients from counterfeit medicines, 
the operation and supervision of clinical trials, 
increasing co-operation through enhancing exchange 
of information and efficient and effective use of 
Photographed at the International 
Summit of Heads of Medicines 
Regulatory Bodies.
Meena Ballantyne, Health Canada;  
andrew C. von Eschenbach, FDA; and 
Pat O’Mahony, Irish Medicines Board.
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scarce regulatory resources. Substantial progress 
was made and agreement reached on the hosting  
of a third meeting in Singapore in December 008.
THE EUROPEAn MEDICAL 
DEVICES REGULATORy 
SySTEM
This was another active year in the European 
Medical Devices regulatory system with the IMB 
participating in a large number of meetings at EU 
level, including the Medical Devices Expert Group 
and the Classification and Borderline Working 
Group. Ireland was appointed to the chair of the 
Compliance and Enforcement working group of  
the EU Competent Authorities. The year also saw 
the publication of Directive 007/47/EC amending 
Directive 9/4/EEC.
COMMUnICATIOnS
In 007, the Board continued to enhance its 
communication with various stakeholder groups 
with an interest in healthcare products. Information 
days for human medicines, veterinary medicines, 
medical devices and wholesaling industry stakeholders 
were held. These meetings attracted a large number 
of attendees and positive feedback was received.
A number of meetings with other organisations  
and individuals with particular interests in healthcare 
products were also hosted during the year.  
These included meetings with the Animal & Plant 
Health Association (APHA), the Association of 
Pharmaceutical Manufacturers of Ireland (APMI), 
the Irish Association of Health Stores (IAHS),  
the Irish Health Trade Association (IHTA), the  
Irish Medical Devices Association (IMDA), the 
national Standards Authority of Ireland, the Irish 
Pharmaceutical Healthcare Association (IPHA), 
Pharmachemical Ireland and the Pharmaceutical 
Distributors Federation.
PUBLICATIOnS
During 007 the IMB launched a number of valuable 
guidance documents as part of its communications 
efforts, all of which are available from our website 
(www.imb.ie).
A number of editions of the IMB’s Medicinal 
Products newsletter, Medical Devices newsletter 
and Drug Safety newsletter were published and are 
available on this website.
FREEDOM OF 
InFORMATIOn
nineteen requests were received under the 
Freedom of Information Act in 007, compared  
with six in 006, reversing the trend of recent years.
THE FUTURE
The IMB faces new challenges and new 
opportunities for development in 008.
The overall workload for the organisation  
continues to increase and ensuring adequate 
staffing and resources to meet the various  
demands is an ongoing challenge. We intend to 
review our structures in the human products area; 
implement a system for notification of unauthorised 
medicines by wholesalers and manufacturers; 
conduct additional inspections in a range of areas 
including tissues and cells establishments; 
implement provisions relating to paediatric 
indications of human medicines; and report on 
implementation of regulation in the cosmetics 
sector.
Our objective will be to maintain the impetus for 
change across the organisation and continue to 
manage change to assist us in delivering higher 
standards of output to all stakeholders. In this 
regard, continuing to develop our performance 
management system will be a priority.
Irish Medicines Board Annual Report 2007

Our staff’s expertise and experience are key  
assets to our organisation. We will continue to  
offer training and development opportunities in 
order to maintain and enhance the skills set  
required for the ever changing and increasingly 
complex areas under our remit. In this regard  
we will prepare for the implementation of  
the Advanced Therapies Regulation in 009.
We will continue the roll-out of our ongoing innovation 
in IT development and linked organisational change 
during 008. These will further develop our information 
technology systems and assessment activity with 
consequential major benefits to the IMB and its 
stakeholders.
We will continue to review our funding provision 
and to look critically at our own cost base to ensure 
maximum use of resources.
BOARD AnD STAFF 
MATTERS
In total, over 00 people contribute voluntarily to  
the work of the IMB through participation on the 
Board and various Committees. The Board and 
Committees had a very successful year in office and 
the access we have to this range of independent 
expertise and acumen is of immense value to the 
workings of our organisations. I thank each member 
for their individual contribution and commitment 
during 007.
I acknowledge the support of the staff of the 
Departments of Health and Children, and Agriculture, 
Fisheries and Food for the work of the IMB.
I welcome all new staff members who joined during 
007 and express my personal appreciation to all 
the staff of the IMB for their continued generous 
support in achieving the Board’s objectives during 
the year. I look forward to the support of all staff  
in dealing effectively with the various challenges 
ahead, as we continue to strive for excellence in  
all aspects of our daily activities.
Pat O’Mahony 
Chief Executive
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huMaN MEdICINES
InTRODUCTIOn
The Human Medicines Department had a very 
successful year in 007. Safety monitoring of 
medicines on the Irish market continued to be a 
core priority and the key focus of the department’s 
staff. Implementation of the revised pharmacovigilance 
structure continued during 007, with further refinement 
of activities within the Market Surveillance and 
Pharmacovigilance assessment teams. This structure 
works closely with the technical assessment teams 
and has proven to be very beneficial. The department 
also managed and contributed to significant levels of 
safety assessments whilst witnessing a substantial 
increase in volume outputs related to licensing 
activities, all managed effectively by the staff of  
the department.
PHARMACOVIGILAnCE
The IMB always places great emphasis on 
encouraging and promoting reports from a range  
of stakeholders in relation to suspected adverse 
reactions to medicines. These reports are important 
to signal potential safety issues from medicines  
in use and ultimately they assist the IMB to monitor 
medicines on the market. During 007, the IMB 
continued to encourage adverse reaction reporting 
and provided regular reminders about reporting in 
the Drug Safety newsletter and its regular publications 
in MIMS (Ireland) and the Irish Medicines Formulary 
(IMF). A number of presentations on pharmacovigilance 
and adverse reaction reporting were also made to 
healthcare professionals as part of undergraduate 
and postgraduate training courses as well as 
continuing education programmes.
During 007 the IMB received a total of ,75 
suspected adverse reaction reports occurring  
in Ireland from healthcare professionals and 
pharmaceutical companies. The IMB greatly 
appreciates the contribution of healthcare 
professionals in reporting this information which 
facilitates the continued surveillance of the safety  
of medicines. The collection and evaluation of these 
reports is essential to ensure constant vigilance as  
to the safety of products and facilitates the IMB  
in ensuring that regulatory action/proposals take 
account of all available case report information.
The IMB recognises the sometimes burdensome 
nature of form-filling for suspected adverse drug 
reactions (ADRs) and values the time healthcare 
professionals and consumers give to this important 
dr. Joan gilvarry, Director of Human Medicines
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task. In 007, the IMB established an online 
reporting system through its website which it is 
hoped will make it easier for participation in this 
process. This new online channel supplements  
the existing options for reporting suspected  
adverse reactions which include yellow cards  
and downloadable report forms. The new online 
option was introduced in november and over 60 
online reports were submitted by year-end. It is 
hoped that uptake of this additional mechanism for 
reporting will continue to increase over the coming 
years. Access to the online reporting system is 
available through the IMB website at www.imb.ie.
In addition, the IMB’s new website now also  
offers users the option of registering their contact 
information to enable them to receive direct and 
immediate notification of IMB alerts/updates by 
email or text message.
BrEaKdOWN OF rEPOrTS  
BY SOurCE
Marketing Authorisation Holders 964
General Practitioners 06
Hospital Doctors 7
Hospital Pharmacists 89
Community Care Doctors 7
Community Pharmacists 70
nurses 67
Patient/Consumers 54
Clinical Trials 44
Dentists 7
Health Care Professionals (other) 7
Total 1,751
Individual case reports were followed up by the IMB, 
with feedback information provided to reporters as 
appropriate. Relevant reports (i.e. serious, suspected 
cases) notified directly to the IMB by healthcare 
professionals were forwarded to the appropriate 
marketing authorisation holders and the European 
Medicines Agency (EMEA) within the agreed 
timeframes and formats. The IMB also continued  
to provide details of reports received to WHO  
for inclusion on their international database.
DRUGS WITHDRAWn/
SUSPEnDED FOR  
SAFETy REASOnS
Nimesulide
In May 007, the IMB suspended the marketing 
authorisations for oral nimesulide products. This 
action was taken following evaluation of new and 
cumulative safety data related to hepatotoxicity, 
indicating that oral nimesulide could no longer be 
considered safe under normal conditions of use. 
Healthcare professionals and patients were informed 
of this urgent regulatory action through notices 
placed in the print media, as well as direct  
contact with a range of professional organisations.  
A freephone helpline dealt with some ,500 enquiries, 
within the first few days of the suspension and  
the IMB’s website was a resource for information 
through statements and a Q&A document.
At the time of suspension, nimesulide was 
authorised in 7 EU Member States. The national 
suspension of a product authorisation, by virtue  
of current European (EU) medicines legislation, 
automatically triggers a European procedure of 
review and assessment of the issues leading to  
the national regulatory action. In accordance with 
this procedure, scientific review is first carried out 
by the scientific Committee for Medicinal products 
for human use (CHMP) of the European Medicines 
Agency. This is followed by a European Commission 
review and its decision, once issued, is legally 
binding on EU Member States.
The CHMP review procedure for nimesulide 
concluded in September 007 and the recommendation, 
which was agreed by a narrow majority, was that 
nimesulide-containing products for systemic use 
should be allowed to remain on the market in EU 
Member States, subject to further restrictions. This 
recommendation was communicated to the European 
Commission for consideration and the outcome of 
its deliberations was awaited at the end of 007.
notwithstanding the CHMP position, the IMB’s view 
remains that the risk/benefit profile of nimesulide 
for systemic use is unfavourable and suspension  
of the authorisations for such products currently 
remains in place in Ireland.
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InTERnATIOnAL 
COLLABORATIOn
The ChMP Pharmacovigilance  
Working Party (PhvWP)
There were a total of  meetings of the CHMP’s 
PhVWP during 006. During these meetings, the 
PhVWP considered product-related issues at the 
request of CHMP. These included centrally-
authorised products, products subject to referral 
procedures and nationally-authorised products. 
Other product-related issues were also considered 
at the request of the competent authorities of the 
Member States.
The PhVWP continued its regular interaction with 
the FDA through tele/videoconferences held during 
PhVWP meetings.
Following extensive update of EU pharmacovigilance 
guidelines to take account of both new and expanding 
responsibilities for marketing authorisation holders 
and national competent authorities, the European 
Commission issued Volume 9A of the Rules 
Governing Medicinal Products in the EU (Guidelines 
on Pharmacovigilance for Medicinal Products for 
Human Use) in January 007.
PhVWP drafting groups continued to review and 
develop guidance on other organisational issues  
and to consider relevant class-related effects.
Information was provided by the IMB Pharmacovigilance 
Section in respect of all requests circulated via the 
Rapid Alert/non-Urgent Information exchange system 
by other Member States.
WhO/ISOP
IMB staff participated in and presented at the 
annual meeting of national centres involved in the 
World Health Organisation (WHO) international drug 
monitoring programme and at the annual International 
Society of Pharmacovigilance (ISOP) conference, 
both of which were held in October, 007.
Electronic reporting
The IMB continued to report all suspected serious 
adverse reactions occurring in Ireland electronically 
via EudraVigilance to the EMEA and to those 
companies with which satisfactory testing has  
been completed. By the end of 007, 59 companies 
(an increase from  companies at the end of 006) 
were in production with electronic reporting to the 
IMB, with a further nine in active testing.
Detailed information and guidance on electronic 
reporting is available in the IMB Guide to Electronic 
Submission of ICSRs and SUSARs Associated with 
Use of Human Medicines, which can be located 
under the heading ‘Publications’ on the website.
During 007, IMB staff participated at all 
EudraVigilance meetings and training courses 
organised by the EMEA.
Publications
Two issues of the IMB’s Drug Safety newsletter 
were circulated to doctors, dentists and pharmacists 
during 007. These included a further update on 
experience with BCG vaccine; recommendations 
regarding safety and use of triamcinolone acetonide 
and terbinafine; the potential for interaction 
between glucosamine and warfarin; as well as  
the outcomes of several safety reviews related  
to neuroleptics, nSAIDs, piroxicam, desmopressin 
nasal spray and botulinum toxin. Copies of the 
newsletters and updates on safety issues 
considered to be of public health interest were 
published in the IMB’s regular article in MIMS 
(Ireland) during the year and are available from  
the Publications section of the IMB’s website  
www.imb.ie.
Company Liaison
Advice on IMB pharmacovigilance reporting 
requirements was provided to marketing authorisation 
holders (MAHs) on request throughout the year. 
Anonymised cumulative adverse reaction data was 
provided to MAHs in respect of their products on 
request and in the case of individual serious suspected 
adverse reactions associated with use of their products, 
on an expedited basis.
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Company/sponsor compliance with pharmacovigilance 
obligations was monitored on an ongoing basis.  
This was undertaken through review and monitoring 
of the timeliness and quality of individual adverse 
reaction reports, evaluation of the follow-up 
information provided for individual reports, assessment 
of the quality and comprehensiveness of periodic safety 
update reports and annual safety reports and responses 
to IMB requests for pharmacovigilance data.
haemovigilance
The IMB continued to participate in the steering 
committee established by the Department of Health 
and Children (DoHC) to oversee implementation of 
relevant EU and national legislation. A report on the 
outcome of review and evaluation of the haemovigilance 
system in place in Ireland prepared by an independent 
expert at the request of the DoHC in 006 was 
considered by the Committee. The DoHC indicated 
its intention to examine the report in detail, including 
proposed recommendations and to keep the 
Committee informed of progress in this regard.
The IMB continued its regular meetings with the 
national Haemovigilance Office (nHO). These 
meetings involve reviewing reported haemovigilance 
events, discussing issues of mutual concern and 
contributing to the development of guidance on 
haemovigilance reporting. In addition, consideration  
was given to further developments to facilitate 
monitoring and revised working practices necessary  
to meet the provisions of the EU and national 
legislation. The IMB collaborated with the nHO  
in the preparation of a Haemovigilance Handbook, 
which has been available on the nHO website since 
July 007. The IMB also participated in a workshop 
arranged by the DoHC in June 007 on haemovigilance 
issues which included reporting requirements. 
Presentations outlining the overall roles and 
responsibilities in relation to haemovigilance 
obligations and the inspection process were 
provided by the IMB.
The IMB attended the annual European Haemovigilance 
network (EHn) conference, which took place in 
Dublin in March 007. This was a useful forum at 
which issues regarding definitions and standards for 
reporting practice were discussed and developed, 
with a view to harmonising requirements across  
the EU. Harmonisation initiatives have since been 
progressed by the EU Commission which convened 
a Working Group on Haemovigilance, which met  
in December 007 and which was attended by the 
IMB and nHO. The aim of this group is to determine 
a common approach to the provision of data by 
Member States to the European Commission.
Tissue and Cell vigilance
In August 007, S.I. 598 of 007 was signed by the 
Minister for Health and Children which transposed 
Directives 004//EC and 006/86/EC into national 
law. This S.I. specifies the responsibilities regarding 
traceability requirements, notification of serious 
adverse reactions and events as well as certain 
technical requirements for the coding, processing, 
preservation, storage and distribution of human 
tissues and cells.
During 007, the IMB attended and participated  
at relevant vigilance and surveillance meetings to 
facilitate monitoring and revising working practices 
as necessary to meet the provisions of the legislation. 
At national level, the IMB continued to participate  
in the steering committee established by the DoHC 
and to contribute to relevant workshops.
At European level, the IMB participated in relevant 
initiatives including the joint WHO/EU project for 
Standards and Training for the Inspection of Tissue 
Establishments (EUSTITE). This project aims to 
promote standardisation to best practice in the 
inspection of tissues and cells, and in partnership  
with the WHO, to develop optimal systems for the 
notification and management of adverse events and 
reactions relating to the quality and safety of tissues 
and cells. The IMB acted as co-rapporteur at the 
EUSTITE meeting on Vigilance and Surveillance of 
Human Tissues and Cells for Human Application in 
the European Union and Globally, which took place 
in Rome in July 007.
During 007, the IMB received 9 reports 
associated with use of tissues and cells, 4  
of which met the reporting criteria, including one 
adverse reaction and  adverse events. Each 
report was followed up individually, with feedback 
provided to all reporters. An update on experience 
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with adverse reaction/event reporting was issued  
in August 007, to all tissue and cell establishments, 
reflecting information received during the first year 
following introduction of the legislation.
Information on reporting requirements, including a 
‘Guide to Reporting SARs/SAEs’ and downloadable/
online versions of the report forms are available on 
the IMB’s website.
nEW PRODUCTS 
AUTHORISED
During 007, the IMB output for new product 
applications was ,08. This comprised 09 new 
national and parallel import applications, 40 new 
mutual recognition (MR) and new decentralised 
(DCP) applications, 88 new centralised* and  
45 transfer applications.
(* Total number of centralised applications complete 
in 2007, not all may be authorised by the European 
Commission at this point)
The following table shows the distribution of these 
over the last number of years:
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This total output figure displays an increase primarily 
due to an increase in the number of applications 
submitted through the centralised and decentralised 
procedures.
VARIATIOnS AUTHORISED
During the year, there was an output of 4,50 
variations to product authorisations for products 
authorised through the national or MR procedures. 
This was a slight decrease from 006 due to a 5% 
decrease in the number of variations applications 
received which was 4,44.
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REnEWALS AUTHORISED
During the year, there was an output of ,0 
renewals to product authorisations for products 
authorised through the national or MR systems.
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CLInICAL TRIALS 
AUTHORISED
During 007, 4 applications to conduct clinical 
trials were approved by the IMB. This represents a 
similar figure to that of 006 and 005 as depicted 
in the table below.
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Also in 007 there was an output of 485 clinical  
trial amendment applications, which represents  
an increase from the 006 figure of 409.
There was a slight decrease in the total input of 
new, variation, renewal and clinical trial applications 
in 007 and the total output of these applications 
continued to meet the total input as shown in the 
graph below.
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EUROPEAn COMMITMEnTS
Our commitments to the European Regulatory process continued to be substantial in 007. The 
department’s technical staff serviced the following committees and working parties at the European 
Medicines Agency.
Committee/Working Party duration/Frequency
Committee for Human Medicinal Products (CHMP) 4 days/month
Committee for Orphan Medicinal Products (COMP)  days/month
Co-ordination Group for Mutual Recognition & Decentralised Procedures  
(CMD (h))  days/month
Committee on Herbal Medicinal Products (HMPC) 4 days/ months
Paediatric Committee (PDCO)  days/month
Gene Therapy Working Party (GTWP) 6 days/year
Pharmacovigilance Working Party (PhVWP)  days/month
Safety Working Party (SWP)  days/ months
Quality Working Party (QWP)  days/ months
Vaccine Working Party (VWP)  days/ months
Scientific Advisory Groups (SAG)  days/month
Efficacy Working Party (EWP)  days/ months
Biological Working Party (BWP)  days/month
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vETErINarY MEdICINES
InTRODUCTIOn
The year under review marked a year of significant 
change for the department. A new management 
structure and workflow system were introduced 
into the department to improve efficiencies. Record 
outputs were achieved again in 007. A further 
significant development, consequent to changes in 
national legislation on the distribution of veterinary 
medicines, was the development of a new policy in 
relation to the method of supply of veterinary vaccines.
PHARMACOVIGILAnCE
A total of 9 reports of suspected adverse reactions 
associated with the use of authorised veterinary 
medicinal products were received by the IMB during 
007. Of those, 7 reports were received from 
marketing authorisation holders and 0 originated 
directly from veterinary practitioners. In those 
reports, a total of 6 veterinary pharmaceutical 
products and 40 immunological products were 
identified as possibly associated with adverse 
effects. While the majority of reports related to the 
use of a single veterinary medicinal product, two or 
more veterinary medicinal products were identified  
in ten reports.
Suspected adverse events were reported in the 
following species: human (four reports), bovine (), 
canine (5), ovine (five), equine (six), feline (seven), 
porcine (one) and rabbit (one).
Of the 9 reports associated with the use of 
veterinary medicinal products, 7 related to 
suspected adverse reactions in the treated animals, 
4 related to lack of expected efficacy, one related 
to a suspected residue violation and four cases 
involved suspected adverse reactions in individual 
users following exposure to a veterinary medicinal 
product. no regulatory actions were taken in 007 
as a result of the safety information received in the 
form of spontaneous adverse reaction reports.
The IMB is committed to promoting veterinary 
pharmacovigilance in Ireland and gratefully 
appreciates and acknowledges the efforts of 
reporters in providing pharmacovigilance information 
to the IMB and responding to requests for 
clarification.
dr. J.g. Beechinor, Director of Veterinary Medicines
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OUTPUTS
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IMB personnel were active in centralised procedures 
both for new medicines and referral procedures during 
the year. Applications for variations to veterinary 
product authorisations continue to form the main 
bulk of total applications received, reaching 945 for 
the year and accounting for 7% of total outputs.  
A noticeable feature was the decline in the number 
of new applications submitted for evaluation using 
the national procedure;  such applications were 
received during 007 compared to 47 in 006.  
A corresponding increase in the number of 
applications submitted for assessment under the 
mutual recognition system was noted and reflects 
the growing importance of the procedures for joint 
assessments undertaken with the involvement of 
other Member States.
The department was very active as reference 
member state in the European mutual recognition 
and decentralised procedures, with more applications 
than all other member states in the European 
Community in 005 and 006. While official data  
on the IMB position relative to those of other EU 
member states for 007 are unavailable at the time 
of writing, the department dealt with a record number 
of procedures during the year as seen from the 
following chart. The department continues to 
position itself so that it can continue to play a 
leading role acting as reference member state  
in the years ahead.
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During 007, the number of applications for 
determination of a product as either within or  
outside the scope of the national legislation on 
animal remedies declined, continuing the trend  
of previous years. There were comparatively  
few clinical trial applications as seen in the  
chart on the next page.
Irish Medicines Board Annual Report 2007

Clinical trial applications are regulated by the 
Department of Agriculture, Fisheries & Food  
which seeks the advice of the IMB prior to  
granting approval for them.
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Classification Enquiries
Clinical Trial Applications
With a change to national legislation adopted in 
007, the IMB is now able to grant exemptions 
from the requirement for a marketing authorisation 
for animal remedies intended solely for aquarium 
fish, caged birds, homing pigeons, small rodents, 
ferrets and pet rabbits. In order to benefit from  
this legislation, applicants should apply to the IMB 
using the classification enquiry system. While no 
applications for exemption were received during 
007, it is expected that a number of such applications 
will be submitted to the IMB during 008.
MAnAGEMEnT
A new management structure took effect in February 
007. This team is comprised of the Director of 
Veterinary Medicines and three section managers 
(Planning & Licensing, Quality, and Safety & Efficacy). 
This group spearheaded the development of new and 
significant changes in the business systems which 
underpin the management of applications within the 
department. Both pharmaceutical and immunological 
products now follow the same evaluation and 
management processes. new systems for the 
administrative management of applications and 
associated communications were also put in place. 
These new systems ‘went live’ in June and have proved 
highly effective. The department spent considerable 
time during the year updating its standard operating 
procedures which govern the authorisation procedures 
consequent to the changes in business processes 
and in accordance with corporate IMB standards.  
In addition, significant recruitment of scientific and 
non-technical personnel also took place. notwithstanding 
the various internal initiatives within the department, an 
effective and successful year of outputs was recorded.
COMMUnICATIOnS
IMB staff held several meetings with the Department 
of Agriculture, Fisheries & Food, the Animal and Plant 
Health Association, other stakeholders and individual 
companies during 007. The department also held a 
Vet Information Day and published four news articles 
relating to the regulation of veterinary medicines. The 
department participated in the development of a new 
IMB website. It hopes that this site will become the 
most authoritative and useful source of information 
on veterinary medicinal products in Ireland.
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In December the department commenced a test 
phase of its automated email notification system  
for the validation and progression of applications  
to applicant companies. Emails generated from this 
system provide summary information on the status 
of the application as it progresses through various 
milestones of the evaluation procedure. On completion 
of the test phase, the system is expected to be 
rolled out to all applications in February 008.
At an EU level, 007 saw the publication of a report 
from the task force on availability of veterinary 
medicines in Europe http://www.hma.eu/0.html. 
This task force was chaired by the Director of 
Veterinary Medicines.
Through their involvement in committees of the 
European medicines network of regulatory agencies 
including the European Medicines Agency, personnel 
from the department played a useful role in influencing 
EU policies and in elaborating regulatory guidance. 
Recognising the strategic interest of the animal 
health industry in having as many shared products 
as possible between UK and Ireland, personnel from 
the department continued work with colleagues 
from the UK’s Veterinary Medicines Directorate with 
the aim of achieving joint or dual labels of common 
products. Given the different legislation and structures 
which exist in the two territories, this remains a 
challenging but worthwhile objective for the IMB.
A significant development during the year was the 
elaboration of a revised IMB policy on the supply  
of veterinary vaccines. This policy was developed  
by a working group of scientific experts operating 
under the aegis of the IMB’s Advisory Committee 
for Veterinary Medicines (ACVM). The objective  
of the working group was to review the available 
methods of supply of vaccines and prepare a 
guidance document on the most appropriate criteria 
to be considered when allocating vaccines to one  
of the available supply routes. The working group 
held consultations with interested parties and 
stakeholders. It received a total of  submissions 
and prepared a report for the ACVM in October.  
A further round of public consultation on the draft 
report yielded nine more submissions which were 
considered by the IMB before the final report was 
adopted in november. The report, together with a 
report on the outcome of the consultation process, 
is available on the IMB website. IMB policy on this 
matter will henceforth be in accordance with the 
conclusions of the report. The IMB wishes to thank 
the experts involved in developing the report and all 
those who took time to provide input into the 
process.
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MEdICaL dEvICES
InTRODUCTIOn
The year 007 was a busy and productive year  
for the medical devices department. Monitoring of 
safety issues on the marketplace continued to be a 
core focus of day-to-day activity. Significant activity 
took place in the areas of vigilance, compliance and 
clinical investigations.
During the year, the department implemented  
a major restructuring programme resulting in  
an organisational structure which more closely 
reflects its needs and facilitates further growth.  
A key element involved the introduction of a 
management team with responsibility for three  
core process areas, pre-market, post-market and 
audit. The new organisational model caters for  
an increased focus on operational management, 
supports increasing workload, improves the 
alignment of technical skills and resources,  
allows for an integrated focus on market compliance 
activities and facilitates the incorporation of new 
products and technologies.
The Advisory Committee for Medical Devices 
(ACMD) met three times in 007. Topics under 
consideration included medical devices in the 
community setting, point-of-care testing, review of  
the medical devices directive and vigilance issues. 
The ACMD also assisted with the preparation  
of a safety notice in relation to medical devices 
prescribed for use in the community setting and  
it contributed to the development of the guidance 
note for ethics committees.
VIGILAnCE
A total of 840 vigilance reports were received and 
assessed in 007, representing a decrease on the 
006 figure of 99. This decrease was due to multiple 
factors including the continued low numbers of 
Competent Authority reports being circulated by 
Member States. It is anticipated that reports will 
increase significantly in 008 as a result of the improved 
clarity in the revised guidance on the medical device 
vigilance system (MEDDEV .- rev 5).
Ms. ann O’Connor, Medical Devices Director
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Some 456 vigilance reports were received from 
manufacturers, 08 were received from other 
regulatory agencies and 75 were received directly 
from medical device users. Class IIb general medical 
devices and general category in-vitro diagnostic 
medical devices (IVDs) represented the largest 
number of reports received, 4 and 59 respectively. 
An increase in the number of class I device issues 
was also noted.
Single use, non-active implantable and electro-
mechanical medical devices represented the most 
common reports received per product family, which 
include devices such as, assistive technology devices, 
ophthalmic devices, e.g. contact lens solutions, and 
devices incorporating software, e.g. defibrillators. In 
the IVD area a large number of the reports related to 
clinical biochemistry and blood transfusion devices.
The principal issues encountered during 007 included 
software problems and concern surrounding the 
maintenance and management of devices particularly 
in the area of technical aids for disabled people, 
walking frames and wheeled mobility devices. 
Other issues included mislabelling of IVDs.
RECALLS
During 007, the IMB received  field safety 
corrective actions relating to medical devices that 
directly impacted the Irish market. These resulted  
in a combination of 4 product removals, 9 field 
safety notices, 59 software upgrades and 9 hardware 
modifications. The implementation of corrective 
actions was closely monitored by the IMB.
In 007, the IMB closely co-operated with other 
European Competent Authorities, the European 
Commission and medical device manufacturers  
on several major issues which needed input from  
a variety of stakeholders.
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FaMILY grOuPS OF dEvICES IMPLICaTEd  
IN vIgILaNCE rEPOrTS IN 2007 – In-VItRo 
dIagNOSTIC MEdICaL dEvICES
0
20
40
60
80
100
120
140
12
122
0
8 9
34
23
13
1
B
lo
od
 T
ra
ns
fu
si
on
C
el
lu
la
r 
P
at
ho
lo
gy
C
lin
ic
al
 B
io
ch
em
is
tr
y
C
oa
gu
la
tio
n
H
ae
m
at
ol
og
y
Im
m
un
ol
og
y
M
ic
ro
bi
ol
og
y
V
iro
lo
gy
U
nd
et
er
m
in
ed
OuTCOME OF FIELd SaFETY COrrECTIvE 
aCTION IN 2007
0
50
100
150
200
250
119
55
224
59
3
A
dv
is
or
y 
N
ot
es
Fi
el
d 
M
od
ifi
ca
tio
n
S
of
tw
ar
e 
U
pd
at
e
P
ro
du
ct
 R
em
ov
al
Tr
ai
ni
ng
nOTIFIED BODIES
The IMB conducted three surveillance audits on the 
Irish notified body, national Standards Authority of 
Ireland (nSAI), in 007. The first audit conducted in 
early 007 was a follow-up audit in relation to issues 
identified in audits of certification process and auditor 
performance in 006. Two further surveillance audits 
to the medical device directive (MDD), the active 
implantable medical device directive (AIMDD) and 
the in-vitro diagnostic medical device directive 
(IVDD) took place. Of these two audits, one took 
place at the premises of nSAI in Ireland and the 
second at nSAI’s office in the United States of 
America. All of the issues raised at these audits 
have been satisfactorily addressed.
Two satisfactory observed audits were conducted 
on the nSAI auditors to the MDD and IVD in 007.
A peer review of the IMB performance was undertaken 
by the Danish Medicines Agency in 007. This peer 
review system has been established by the European 
Union’s notified Body Operations Group, a group in 
which the IMB is an active participant. A report was 
completed and the findings were shared by the 
Danish Medicines Agency which revealed many 
common issues and approaches with regard to 
notified body management.
CERTIFICATES OF  
FREE SALE
In 007, 4 certificates of free sale for medical 
devices were issued, which represented a 4% 
increase over 006 figures. In 007, the quality  
of the applications and related documentation for 
certificates of free sale received from medical 
device manufacturers were a cause for concern. 
The IMB highlighted these concerns to the trade 
federations and relevant manufacturers to seek 
rectification and improvements.
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REGISTRATIOnS
There were 6 new notifications/amendments  
in 007 to the register for medical devices. A total 
of 9 IVD medical devices and  GMDs were 
registered. The number of new device manufacturers/ 
organisations registered was .
CLInICAL InVESTIGATIOnS
During 007, three new clinical investigation 
applications for general medical devices and 
amendments to four previous clinical investigation 
applications were received under S.I. no. 5 of 
994. One application for a device for use on 
compassionate grounds was received.
The IMB continues to promote an open and 
transparent approach to clinical investigation 
applications. It encourages clinical investigation 
sponsors to meet with the IMB prior to application 
to discuss the requirements and the process. 
During 007, the IMB continued to work with 
clinicians interested in the area of medical device 
research to clarify legislative requirements and 
discuss issues relevant to Irish investigators. An 
informative guidance document on medical device 
investigations aimed at research Ethics Committees 
was completed and will be published in early 008.
CLASSIFICATIOnS
Fifty classification queries were received in 007, 
54% originating from other Competent Authorities 
and 0% originating from external stakeholders. A 
number of these queries require further discussion 
at the European Medical Devices Expert Group 
Classification/Borderline Working Group.
POST MARKET 
SURVEILLAnCE ACTIVITIES
During 007 there were 89 compliance cases 
opened, equal to the 006 figure. Some 65% 
related to the withdrawal or suspension of a CE 
certificate by notified bodies throughout Europe for 
a variety of medical devices. Missing or incorrectly 
attached CE marking accounted for another 6% of 
cases. Other problems identified and investigated 
as part of compliance cases in 007 included 
labelling, classification and registration issues. 
Requests for assistance from other European 
Competent Authorities accounted for 4% of  
cases. In 007 there were also a small number  
of compliance cases relating to counterfeit  
medical devices investigated.
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The IMB’s proactive compliance activities in  
relation to procedure packs and continuous positive 
airway pressure machines were concluded in 007. 
From this recommendations were made to develop 
legislation governing the regulation of distributors of 
medical devices. Discussions are ongoing with the 
Department of Health and Children in this regard.
The second phase of this compliance activity 
relating to procedure packs focussed on medical 
device systems during 007. A review of the  
IMB register to identify systems manufacturers  
was undertaken and compliance visits conducted. 
non-compliances were raised with the manufacturers 
and corrective actions identified. It is expected that 
this activity will be completed during 008.
The department also contributed to the European 
Commission study on distribution channels for medical 
devices: combating counterfeit medical devices and 
safe medical devices in the distribution chain.
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In 007, four post-market surveillance audits were 
carried out. Two manufacturers were audited following 
issues arising from the marketplace, while the remaining 
two audits were proactive post market surveillance 
audits. The programme of custom-made device 
audits continued in 007 and a total of 0 audits  
took place.
PUBLICATIOnS
In 007, the following guidance documents were 
published or updated for stakeholders:
Guidance Note 7:  
The Vigilance System for Medical Devices.
Guidance Note 8:  
Field Safety Corrective Actions for Medical Devices 
and In-Vitro Diagnostic Medical Devices.
Guidance Note 13:  
Incident Reporting for GMD’s and AIMD’s.
Guidance Note 18:  
Guide to Adverse Incident Reporting for IVD’s.
The IMB safety notices which were circulated  
in 007 were:
IMB Safety Notice SN2007(01): 
Shelhigh Implantable Devices
IMB Safety Notice SN2007(02): 
Clearview HCG Pregnancy Test Kit
IMB Safety Notice SN2007(03): 
Scholl Freeze Verruca and Wart Remover
IMB Safety Notice SN2007(04): 
Mini lift stand Aid
IMB Safety Notice SN2007(05): 
EVAQUA Breathing Circuits
IMB Safety Notice SN2007(06): 
Medical Devices Recommended by Healthcare 
Institutions for Use in a Community Setting
A position paper was published in 007 on the area 
of manufacturing/adaptation of splints and splinting 
material by professional users.
Three medical device newsletters were issued 
during 007 which continue to be well received by 
stakeholders. Many contributions were received to 
newsletter articles from the academic and 
healthcare sectors and from industry, highlighting 
many different medical device issues.
COMMUnICATIOn
An information day was held on the ‘Revisions  
to the Medical Devices Directive 9/4/EEC and 
Vigilance MEDDEV’. This event was attended by 
manufacturers, distributors, healthcare professionals 
and various other interested stakeholders. The  
mix of presentations from the IMB, the Industrial 
Development Agency, the European Commission 
and the German Competent Authority, BfArM, 
provided participants with some key practical 
information and advice.
In 007 the IMB played an active role in the 
Consultative Group for point-of-care testing with  
the Faculty of Pathology, the Academy of Medical 
Laboratory Science and the Association of Clinical 
Biochemists in Ireland to develop guidance for  
the safe and effective management and use of 
point-of-care testing in the healthcare setting.  
The guideline will be published in Spring 008.
EUROPEAn ACTIVITy
During 007, the IMB participated in a number of 
European meetings of the Medical Devices Expert 
Group and its related working groups. It contributed 
to the development of the revised guideline on the 
vigilance system for medical devices MED.DEV .- 
rev 5. This guidance document was published by 
the European Commission in April 007 and is 
available on their website. The IMB proposed a  
new communication system between Competent 
Authorities in relation to vigilance issues. This was 
agreed, piloted and subsequently adopted.
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The Classification and Borderline Working Group 
also met in 007. Decisions emanating from this 
group were published and can be found on the EU 
Commission website. Contribution continued to the 
discussions in the group in relation to the appropriate 
classification of products used in in-vitro fertilisation 
and assistive reproductive therapies.
Ireland was appointed to the chair of the Compliance 
and Enforcement working group of the EU Competent 
Authorities for medical devices. The focus of this working 
group is to provide a forum for co-operation between 
Member States and encourage the development of 
harmonised best practice at EU level.
The IMB continued its participation in the Clinical 
Evaluation Task Force which included involvement in 
a small subgroup to draft a checklist for Competent 
Authorities regarding clinical investigation notification 
reviews. In 007, contributions were made to the 
development of the task force’s guidance document 
on clinical investigations involving coronary stents. 
The task force was also involved in discussions with the 
European Medicines Agency (EMEA) on a proposed 
document on requirements for medicinal substances 
when used in the context of drug-eluting stents.
The IMB participated in the EU Commission workshop 
and resulting working group which proposed to 
classify variant Creutzfeldt-Jakob disease (vCJD) 
assays as Annex II, List A devices in accordance 
with the IVD Directive 98/79/EC. This was broadly 
supported at EU level but requires the drafting of a 
minimum technical specification for all vCJD assays.
COSMETICS
In October 007, a cosmetics project officer was 
appointed to the department to determine the 
legislative obligations and responsibilities of the  
IMB in assuming the role of Competent Authority 
for cosmetics in Ireland. This has involved close 
interaction with the current Competent Authority, 
the Department of Health and Children and other 
stakeholders. The activities of the European Council 
Working Group on cosmetics are being closely 
monitored, as a recast of the cosmetics directive  
is proposed for adoption which aims to strengthen 
the legislation in a number of key areas including 
definitions, good manufacturing practice and post 
market surveillance. The IMB also attended as an 
observer to a number of European meetings relating 
to cosmetics including the Standing Committee on 
Cosmetic Products, the Working Group on Cosmetic 
Products, and the Platform of European Market 
Surveillance Authorities in Cosmetics.
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COMPLIaNCE
InTRODUCTIOn
The year 007 was a productive year for the 
department which witnessed increased activities 
across its five sections of Licensing, Inspection, 
Market Compliance, Enforcement and Planning.
Changes necessitated by the new Medicinal 
Products Regulations (Control of Manufacture, 
Control of Wholesale Distribution, Control of Placing 
on the Market and Control of Advertising) and by 
the European Communities (Animal Remedies)  
(no. ) Regulations, 007, were implemented.  
A further set of Regulations relating to the phased 
implementation of the Tissues and Cells Directive 
were also put in place.
Outlines of the key activities and relevant findings 
are set out below under each of the sections.
LICEnSInG
During 007, there was an increase of 4%  
in licensing activities. The licence/authorisation 
applications received covered the range of 
manufacturers of human and veterinary medicines, 
wholesalers (human), manufacturers of investigational 
medicinal products, blood establishments and tissue 
establishments. In total, 0 new licences/authorisations 
were issued, four of which were blood establishment 
authorisations. One wholesaler’s authorisation was 
revoked. In relation to tissue establishments,  
0 applications were received in 007.
A total of 78 variations were processed and issued, 
compared to 485 in 006 and 45 in 005.  
Technical variations increased by 8%.
Mr. John Lynch, Director of Compliance
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The total number of licences/authorisations in force 
is presented below.
Total Number  
of Licences/ 
authorisations 2005 2006 2007
Human 85 8 85
Veterinary 0 0 8
Investigational 
Medicinal Products 7 6 4
Wholesaler 9 48 7
Blood 
Establishments 0  4
Tissue 
Establishments 0 0 0
Laboratory 
Certificates 0 8 
The licensing section continued to support the 
inspection section in relation to the issuing of GMP 
certificates within 90 days following an inspection.
Controlled drugs Licensing
During 007, a total of ,665 controlled drugs 
licences were issued compared to ,585 issued in 
006. Segmented activity levels are set out below.
Controlled drugs  
Licensing activity 2006 2007
Registration 6 9
Export & Import 944 964
Annual – new 0 9
Annual – Renewal 5 7
LOnO 4 47
Pilgrims  4
Hemp 0 5
Export Certificates
There was an output of ,758 export certificates as set out below.
Product Certification activity 2005 2006 2007
Certification of Documents 05 89 6
Certificates of Free Sale 8 5 5
Certificate of Good Manufacturing Practice for Finished Product Manufacturers 8 4 00
Certificate of Good Manufacturing Practice for Active Substance Manufacturers 8 4 6
Certificate of a Pharmaceutical Product for Human Use 974 9 94
Certificate of a Pharmaceutical Product for Veterinary Use 0 97 05
Other 0 69 8
Total 1,729 2,050 1,758
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EU PROJECTS
During the year, the licensing section and the IT  
and Change Management Department continued to 
participate in the Eudra GMP EMEA project group. 
The purpose of this group is to establish a database 
of all manufacturers of medicinal products in the 
European Economic Area (EEA). The database was 
launched during April 007 and contains information 
on all manufacturing importation authorisations 
(MIAs) issued by EEA competent authorities. It also 
contains information on GMP certificates, which 
Member States issue following each GMP 
inspection. EEA competent authorities currently 
have full access to the EudraGMP database.
Other features planned for future releases of the 
EudraGMP include:
n Member States will be alerted in cases of GMP 
non-compliance, faulty manufacture, suspension 
and/or revocation of MIAs.
n Access by the general public to MIAs and certain 
GMP certificates, with the exception of any 
information of a commercially and/or personally 
confidential nature
n Discussions with MRA partners are ongoing  
and the aim is to eventually eliminate the paper 
exchange of certificates
n non-compliance information will also be included 
in the database if the outcome of the inspection is 
that the manufacturer does not comply with GMP.
n Sharing of information on planning inspection 
schedules in third countries (i.e. outside the EEA) 
will facilitate best use of resources and avoid 
duplication of inspections in third countries.
InSPECTIOn
good Practice Inspection activities
The inspection function carried out 56 inspections 
in 007 across the four operational areas:
n Good Manufacturing Practice (GMP),
n Controlled Drugs and Good Distribution Practice 
(CD/GDP),
n Good Clinical Practice and Pharmacovigilance 
(GCP/PhV), and
n Blood and Tissues
good Manufacturing Practice (gMP)
In 007, 08 GMP inspections were carried out. 
These included ten inspections in third countries,  
six of which were carried out at the request of the 
European Medicines Agency (EMEA) for centrally 
authorised products, and one inspection at the 
request of the European Directorate for Quality of 
Medicines of an active substance manufacturing 
site named on a certificate of suitability to the 
monograph of the European Pharmacopoeia. The 
remaining sites are included on Irish manufacturers’ 
authorisations as third country manufacturing sites.
Controlled drugs
Twenty one controlled drugs inspections were 
conducted, extending the roll-out of the inspection 
programme to include all licensed distributors and 
manufacturers of controlled drugs.
good distribution Practice (gdP)
Sixty inspections were carried out at wholesale 
premises to evaluate compliance with the GDP 
requirements and to assess new authorisation 
applications and variations.
In October, the IMB hosted an Information Day for 
wholesalers and distributors involved in the distribution 
of medicinal products for human use in Ireland.
good Clinical Practice (gCP)
The GCP inspection programme includes inspection 
of sponsor companies, investigators, contract 
research organisations and laboratories and applies  
to clinical trials approved in Ireland and those 
performed in support of national or EU marketing 
authorisations.
During the year, 4 GCP inspections were carried 
out. nine of these were carried out at sponsor and 
investigator sites in Ireland and five were conducted 
at study sites abroad.
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Pharmacovigilance Inspections
Two pharmacovigilance inspections were carried out 
in 007: one at an Irish based marketing authorisation 
holder’s facility and the other at the European site 
where the Qualified Person for Pharmacovigilance 
was located.
BLOOD ESTABLISHMEnT 
AnD BLOOD BAnK 
InSPECTIOn
nine blood establishment inspections were completed. 
The first hospital blood bank annual reports were 
submitted by 7 blood banks and facilities in January. 
Following a review of the reports, 0 blood bank 
inspections were completed by the IMB.
Tissues Establishment inspections
Twelve tissue establishment inspections were 
completed.
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gMP INSPECTIONS BrEaKdOWN – 2007
Irish finished product manufacturers 60%
Contract testing facilities 6%
Foreign active substance manufacturers 1%
Foreign finished product manufacturers 8%
Irish active substance manufacturers 9%
Investigational medicine product manufacturers 15%
MARKET COMPLIAnCE
In 007, the quality defect and recall and the 
sampling and analysis programmes underwent 
significant expansion, and new areas of activity 
were also developed. These included a pilot 
programme of regulatory compliance inspections, 
and a notification system for the supply of exempt 
medicinal products.
REGULATORy COMPLIAnCE 
InSPECTIOnS
The purpose of this pilot programme was to facilitate 
the development in 008 of a defined programme for 
inspecting the premises of marketing authorisation 
holder companies. This programme will enable the 
IMB to inspect key areas of activity at marketing 
authorisation holder companies.
During the pilot phase, two inspections were carried 
out, focusing on areas that had the highest potential 
to impact on the quality, safety and safe use of 
medicinal products. These included advertising  
and promotional activities, the management of 
registered product information, the management 
and communication of regulatory commitments  
and regulatory changes, implementation of changes 
to product information and product labelling in  
the marketplace and the provision of a medical 
information service for healthcare professionals.
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Points for improvement identified by the IMB  
were communicated to pharmaceutical industry 
associations in 007.
EXEMPT MEDICInAL 
PRODUCTS
In 006, the Department of Health & Children 
provided funding to the IMB for a study into the  
use of unauthorised medicinal products in Ireland.  
A project officer was appointed and an extensive 
programme of research and stakeholder 
consultation undertaken.
The study, which continued throughout 007, also 
encompassed the development of a notification 
system whereby companies and other parties 
importing unauthorised medicinal products into 
Ireland for supply as exempt medicinal products,  
are required to submit product information to the 
IMB. The primary purpose of this notification 
system is to facilitate the recall of exempt medicinal 
products when quality defect and other issues arise. 
The notification system was provided for in the 
Medicinal Product Regulations that were published in 
July 007 and the system is due to be implemented 
from the beginning of 008. A report on the project 
was at an advanced stage of drafting by year-end.
THE SAMPLInG & 
AnALySIS PROGRAMME
A risk-based approach is applied to sampling and 
analysis activities. This programme covers authorised 
human and veterinary medicinal products, active 
substances, products intended for export, 
enforcement-related samples, and borderline 
medicinal products. Products which are sampled are 
analytically tested and/or have their packaging and 
labelling examined.
In 007, a total of 469 medicinal product and other 
product types were evaluated; 74 Irish marketplace 
medicinal products and 4 other samples were 
analytically tested, while examination of 8 samples 
focused on labelling examinations. This represented 
an increase of approximately 44% over 006 figures.
analytical Testing activities
The table below provides details of the number and type of samples that were subjected to analytical testing 
during 007.
Product categories subjected to analytical Testing
Number of 
samples analysed
PhYSICO-ChEMICaL aNaLYSIS:
n Active substances
n nationally-authorised medicinal products
n Parallel import authorisations
n Medicinal products authorised via the Mutual Recognition Procedure
n Centrally-authorised medicinal products
n Products manufactured for export
n Borderline products
n Enforcement-related samples

44

0
5


80
MICrOBIOLOgICaL aNaLYSIS:
n nationally-authorised medicinal products
	 EU-collaborative Market Surveillance Samples
 Icelandic Medicines Control Agency samples
6
9
5
Total 188
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The analytical testing programme was assigned to 
pro-active market surveillance work (4%), analysis  
of enforcement-related samples (4%), and problem 
investigation work (5%).
Packaging and Labelling Examination
The table below shows that a total of 8 
authorised medicinal and other products were 
sampled for packaging and labelling examination.
The programme was designed to reflect the fact 
that packaging and labelling errors and non-compliant 
labelling practices account for a large number of 
quality defect and recall issues on an annual basis. 
The programme also addresses medication error 
issues that may be related to product labelling, as 
well as checking for the presence of safety information 
and warning statements on product labelling.
description of  
products examined
Number of 
samples 
examined
Medicinal and other products 
subjected to risk-based compliance 
monitoring for packaging and 
labelling attributes 0
Medicinal and other products 
subjected to Braille-compliance 
checks 7
Medicinal products associated with 
quality defects and/or recall issues 
Medicinal and other products 
associated with IMB Classification 
Committee work 
Total 281
Proactive market surveillance work accounted for 
9% of the products sampled in this area.
The programme is also designed to rapidly react to 
product complaints and other marketplace compliance 
issues which may affect the safety and safe use of 
medicinal products. This accounted for 6% of the 
programme.
Participation in Eu Co-ordinated Market 
Surveillance activities
The IMB actively participated in various EU-wide 
sampling and analysis programmes. Samples from 
four batches of a centrally authorised product taken 
from other EU countries were analysed on behalf of 
the IMB by the Public Analyst’s Laboratory, Galway, 
which is designated as an Official Medicines Control 
Laboratory (OMCL). Samples of five other centrally-
authorised products were taken from the Irish 
market by the IMB for testing by OMCLs in other 
EU countries.
Five mutual recognition products were analysed by 
the Public Analyst’s Laboratory, on behalf of other 
EU Member States, and the IMB also arranged for 
the analysis of  medicinal products, sampled from 
the Irish market, by other EU OMCLs.
Principal Findings from the 2007 Sampling 
and analysis Programme
n Out-of-specification results affecting four 
nationally-authorised medicinal products.  
One product did not comply with its assay 
specification, and three failed to comply with 
their registered appearance specification
n Six analytical test methods, used to assess  
the quality of  medicinal products, were  
found to be deficient.
n Deficiencies were identified in packs of medicinal 
products examined for Braille compliance
n Deficiencies were identified in the quality of over-
labelling associated with parallel imported products
Packaging and labelling complaints associated  
with medication errors were followed up with the 
marketing authorisation holders for the products 
concerned and, in several cases, changes were 
made to the product labelling.
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THE QUALITy DEFECTS  
& RECALL PROGRAMME
Quality defects in human and veterinary 
Medicinal Products
A total of 47 quality defects in human and veterinary 
medicinal products were reported to, or identified 
by, the IMB in 007. This represents a substantial 
increase (7%) over the number of quality defects 
in 006. This increase is largely due to work carried 
out by the market compliance section in promoting 
the reporting of quality defect issues, particularly at 
manufacturer/marketing authorisation holder level.
A total of 446 reports concerned medicinal products 
for human use, and 7 concerned veterinary 
medicinal products.
A total of 7 reports of critical quality defects  
were received, or identified in 007. This represents 
an increase of 06% compared with 006 figures. 
This increase was partly attributed to a sharp increase 
in the number of notifications of quality defects received 
from other Competent Authorities via the Rapid Alert 
network, as well as a significant increase in the number 
of reports received from pharmaceutical companies.
Of the 7 reports, 65 directly affected Ireland, meaning 
that the defective batch of product in question was 
either on the Irish market and/or manufactured in 
Ireland. This represented a threefold increase in the 
number of critical quality defects which affected 
Ireland compared with 006 figures.
These 65 reports concerned medicinal products  
for human use. The issues of concern related to:
n Product contamination
n Various types of packaging and labelling issues
n Concerns in relation to efficacy
n Product mix-up
n Serious adverse reaction issues requiring 
marketplace actions
n Breach of cold chain controls in the product 
distribution system
n Lack of sterility assurance for products intended 
to be sterile
n The development of an unfavorable benefit/risk 
ratio as a result of new safety-related information
n Undeclared active constituent
n Other product safety concerns
n Counterfeit product issues*
* Two counterfeit products identified on markets 
other than Ireland were found to be genuine medicinal 
products manufactured at Irish manufacturing facilities, 
but the packaging components had subsequently 
been counterfeited/tampered with.
For 0 of the 7 critical quality defect reports, it 
was not possible to conclusively determine whether 
the reports concerned products that were on the 
Irish market. This was due to the nature of the 
products in question, and the manner in which they 
are often distributed, i.e. via the internet or other 
unauthorised supply routes. These cases concerned 
certain counterfeit-related reports, as well as 
unauthorised medicinal products containing 
undeclared active ingredients.
Year 2004 2005 2006 2007
Minor Quality Defects 80 40 40 80
Major Quality Defects 67 99 8 6
Critical Quality Defects 50 66 84 7
number of Quality Defect Reports not Justified   9 4
Total Number Quality defects reported/Identified for the Year 310 327 371 473
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7 quality defect and recall notifications were received from Competent Authorities and OMCLs in other 
countries. Each of these reports was investigated to establish the potential implications of the report for the 
Irish market, and, where appropriate, risk-based follow up was undertaken.
arEaS OF QuaLITY dEFECTS 2007
human 
Quality defects 
%
veterinary 
Quality defects 
%
Packaging and/or Labelling Issues 7 6
Stability Issues 0 
non-Compliance with PA/VPA Issues 4 4
Lack of Sterility Assurance and other Product Safety-related issues 9 0
non-Compliance with Specification Issues 5 4
non-Adherence with Cold Chain Requirements 4 0
Particulate or other Product Contamination Issues  4
Product Mix-Up Issues 4 0
Unauthorised Product Issues 7 7
Lack of Therapeutic Efficacy Issues  0
Damaged Product Issues 4 0
Potential Counterfeit Issues 4 0
Product Usage Issues  0
Labelling Similarity Issues 0 0
Other Issues 6 4
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SOurCES OF huMaN MEdICINaL PrOduCT 
QuaLITY dEFECTS
Physicians and Nurses 1
Patients and/or 
Members of the Public 9
IMB Staff Members 36
Companies (Manufacturers, 
Distributors and/or PA Holders) 190
Other Competent Authorities 171
Competitor Companies 1
Other 1
Community Pharmacists 8
Hospital Pharmacists 29
SOurCES OF vETErINarY MEdICINaL 
PrOduCTS QuaLITY dEFECTS
IMB Staff Members 3
The Department of Agriculture, 
Fisheries & Food 6
Companies (Manufacturers, 
Distributors and/or VPA Holders) 7
Official Medicines Control Laboratories 1
Other Competent Authorities 10
Online reporting
In an effort to promote and encourage the reporting 
of quality defects, particularly by community 
pharmacists, the IMB established an online 
reporting mechanism on its website. www.imb.ie.  
It is hoped that this will make it easier for pharmacists 
to report quality defects to the IMB. The IMB wishes 
to also remind pharmacists that the postage paid 
quality defect report card is also a convenient option 
for reports and these report cards are available upon 
request from the IMB’s Market Compliance section.
recalls of human and veterinary  
Medicinal Products
Recalls from the Irish marketplace involving a  
batch or batches of a medicinal product occurred  
in approximately % of the quality defect cases. 
(This was similar to the 0% figure for 006.)
A total of 97 recalls of medicinal products were 
carried out of which 88 related to human medicinal 
products, and nine related to veterinary medicinal 
products.
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BrEaKdOWN OF huMaN MEdICINaL PrOduCT rECaLLS FrOM ThE IrISh MarKET
Year 2004 2005 2006 2007
Packaging and/or Labelling Issues 9 0 4 
Stability Issues 9 7  
non-compliance with MA Issues 4 6 0 5
Sterility Assurance issues and various other Product safety Concerns 5  8 
non-compliance with Specification Issues   4 
non-adherence with Cold Chain Issues 0  0 9
Particulate or other Contamination Issues   4 
Product Mix-Up Issues    
Unauthorised Product Issues 4 0  4
Lack of Therapeutic Efficacy Issues 0 0 0 
Damaged Product Issues  
Product Usage Issues 5 
Other Issues 8 4  4
Total Number 63 68 56 88
BrEaKdOWN OF vETErINarY MEdICINaL PrOduCT rECaLLS
Year 2004 2005 2006 2007
Packaging and/or Labelling Issues 8   
Stability Issues 0 0  0
non-compliance with VPA Issues 0 0 0 0
Sterility Assurance issues and various other Product safety Concerns 0  0 0
non-compliance with Specification Issues   0 
Particulate or other Contamination Issues 0 0 0 0
Product Mix-Up Issues 0 0 0 0
Unauthorised Product Issues 8  0 4
Other Issues  0 0 
Total Number 19 6 2 9
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EnFORCEMEnT
The IMB’s Enforcement section initiated ,97 
cases involving breaches of medicinal product 
legislation during 007, compared to 469 in 006. 
The number of enforcement cases closed in 007 
was 866 as compared to 797 in 006.
aNaLYSIS OF ENFOrCEMENT CaSE aCTIvITY
Others 5
Retail 175
Advertising 55
Import 1,069
Counterfeit 5
Wholesale 22
Internet 38
Mail Order 28
During 007, the IMB detained a total of 88,79 
tablets, 06,44 capsules, .5 litres of liquids and 
40 kg of creams. The substances detained include 
diazepam, zopiclone, tribulus terrestris, ephedrine, 
yohimbine, sildenafil citrate, tadalafil and other 
erectile dysfunction formulations, anti-depressants, 
antibiotics, corticosteroids, weight loss products 
and skin lightening products.
In 007, prosecutions were initiated at the District 
Court (Dublin) against six retail outlets for breaches 
in relation to the sale of paracetamol containing 
products. Three other prosecutions related to the 
supply of prescription only medicinal products. A 
conviction was recorded at naas District Court for the 
unauthorised supply of anabolic steroids by mail order.
In a case resulting from a joint Garda – IMB 
investigation, and prosecuted by the Director of 
Public Prosecutions, a conviction on indictment was 
recorded at the Dublin Circuit Court and a custodial 
sentence handed down for the supply of unauthorised 
medicinal products (anabolic steroids) by mail order.
Authorised Officers from the IMB, Health Service 
Executive (HSE) and the Pharmaceutical Society of 
Ireland (PSI) carried out joint inspections in relation 
to a number of pharmacies.
national and international liaison between the  
IMB and other enforcement agencies, particularly 
Revenue Customs, in Ireland and abroad has 
enabled the IMB to co-operate to stem the 
unauthorised flow of illegal medicinal products  
and medical devices into and out of Ireland. The 
greatest levels of unauthorised supply into Ireland  
of unauthorised medicinal products were from  
India and China.
During 007, the IMB contributed to the following 
international meetings in relation to enforcement 
matters: WHO/IMPACT (International Medical 
Product Anti-Counterfeiting Task Force) nd General 
Meeting; The Council of Europe Group of Specialist 
on Pharmaceutical medicines Anti-Counterfeiting; 
The Permanent Forum on International Pharmaceutical 
Crime; The Heads of Medicines Agencies Working 
Group of Enforcement Officers.
PLAnnInG
The Planning section is responsible for planning 
activities across the department and works closely 
with the other four sections in this regard. It also 
has a role in collating training and liaises with the 
IMB’s central training and development section.  
It is also responsible for reporting on all departmental 
activities.
The main focus of the Planning section in 007 related 
to the compilation of the inspection programme.  
It was also involved in the co-ordination of several 
training and information sessions including the GDP 
Information Seminar which took place in October 
007. This was attended by over 50 delegates 
from the industry.
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INFOrMaTION TEChNOLOgY  
aNd ChaNgE MaNagEMENT
InTRODUCTIOn
The Information Technology and Change Management 
Department plays a key role in supporting the IMB’s 
objectives through the delivery of both technology 
and business services. The principal areas managed 
by this department are technology and communication 
services together with management of the IMB’s 
change management programme.
The IMB has a well established change management 
programme with a strong focus on continuous 
improvement. Examining and implementing 
mechanisms to enhance business processes has been 
a fundamental activity within the organisation since 00.
OVERVIEW – 007
The department’s primary focus is the provision of 
technical support services to over 00 staff. These 
support services include technology procurement, 
installation and management together with first  
and second line helpdesk functions. The department 
also has a clinical database administration role. 
Specialist skills in network, communication and 
security management also reside within the 
department along with project management,  
web and application development expertise.
The year 007 saw further industry uptake on  
the Regulatory Information Online (RIO) system. 
This extranet service has proved very popular  
with online tracking and application submission 
functionality. Eight web-based training sessions  
for industry were held over the course of the year. 
Further development of the service is planned for 
008 and organisations are encouraged to register 
their interest in this system by contacting the IMB 
at helpdesk@imb.ie.
In line with plans for the year the IMB launched its 
new website www.imb.ie. The new site provides 
enhanced reporting mechanisms for adverse 
reactions and quality defects associated with 
medicines and medical devices.
The IMB is active at both national and European 
level and this involvement is reflected in the IT & 
Change Management Department’s participation  
in a wide range of European technology initiatives. 
During 007, the department was represented  
in eight different IT projects at EU level. These 
projects range from telecommunications projects 
(Eudranet) through to the development of centralised 
portals providing medicines information (EudraPharm).
Ms. Suzanne Mcdonald, Director of It and Change Management
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The IMB’s use of workflow technology to assist  
its operations has attracted the interest of many 
international regulatory bodies over the past number 
of years. This trend continued in 007 with visits 
from a number of regulators keen to explore this 
option for their own organisations.
The provision of training to IMB personnel is an 
important aspect of the departments work and over 
00 members of staff received training in 007.
TECHnOLOGy ACTIVITIES
drug Safety Management
The IMB continues to participate actively in the 
EudraVigilance Technical Implementation Group at 
the EMEA. Work commenced on the procurement 
of a new drug safety management system in 007 
with a view to development in 008. new initiatives 
in pharmacovigilance reporting at EU level have 
brought challenges at national level with a 
consequent need to upgrade supporting systems.
human and veterinary Medicines
Workflow systems were subject to further  
upgrades in both the human and veterinary  
licensing areas during 007. The RIO system 
continued to bring new opportunities for process 
improvement. The system allows registered users 
to submit applications to vary product authorisations 
via a secure web location. Some of the benefits  
of the online system include a significant reduction 
in the volume of paper generated and ease of  
use combined with an online tracking facility to 
determine the progress of ongoing applications.
The IMB plans to extend the RIO system to  
the veterinary medicines authorisation areas  
during 008.
New IMB Website
The IMB website at www.imb.ie received a welcome 
upgrade in 007. The new site has been redesigned 
to reflect the key activities within the organisation. 
In addition to the new ‘look and feel’ the site contains 
improved search functionality together with 
comprehensive information on licensed medicines 
for human and veterinary usage in Ireland.
The new site also includes online forms to assist  
in the reporting of adverse reactions and potential 
quality defects for medicines, medical devices, 
tissues and cells. Users are encouraged to register 
on the new website and to utilise the reporting 
forms wherever possible.
Websites are increasingly used as a mechanism  
to deliver important information in a timely fashion. 
The new IMB website has been designed with this 
in mind and the home page reflects current safety 
topics. Those interested in receiving the latest 
medicines or medical device safety notifications  
via email or SMS messaging should register with 
the new website.
Feedback from users has been very positive and 
comments or suggestions for further improvement 
are welcomed at helpdesk@imb.ie.
Medical devices department
Case management tools to assist in the tracking  
and review of medical device workload started 
development during 007 with a view to 
implementation in early 008.
Compliance department
The procurement of new technology to support the 
work of the compliance department commenced  
in 007. Systems to support the licensing of 
manufacturing and wholesale sites, inspection, 
market compliance and enforcement will be 
developed over the coming -month period.
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Technical Support – External
In 007, the IT & Change Management Department 
provided technical support to both the Maltese and 
norwegian agencies.
Eu Projects
The department was active in a wide range of EU 
Telematics projects during 007. These included:
n EudraVigilance (Drug Safety)
n EudraPharm (Medicinal Product Information)
n EudraGMP (Good Manufacturing Practice)
n EudraCT (Clinical Trials)
n Eudranet (Secure network communications)
n eSubmissions (Electronic submissions)
n EU Datawarehousing/Reference Data Modelling
n Product Information Management (PIM)
Change Management Programme
The IMB’s change management programme 
continued throughout 007. The organisation has  
a strong focus on quality and remains committed  
to improvement via a process of continual review.
In 007, the Medical Devices Department successfully 
implemented new organisational arrangements 
following on from an operational review conducted 
in 006. The Veterinary Medicines Department also 
underwent a review in 006 and the subsequent 
changes to the departmental structure went into 
operation in the first quarter of 007.
In the human medicines area a review of the 
organisational arrangements for safety-related issues 
was undertaken in autumn 007. The findings from 
the study were considered in november 007 and  
it was decided to develop a new position with core 
responsibility for human product safety matters 
across the organisation. The implementation of this 
role and ancillary activities will take place in 008 
following the development of a comprehensive 
project plan.
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ChIEF ExECuTIvE’S OFFICE
PERMAnEnT SECRETARIAT 
OF THE HEADS OF 
MEDICInES AGEnCIES
The personal assistant to the Chief Executive 
continued as a member of the HMA Permanent 
Secretariat and is one of the two remaining original 
members of the group, giving 50% of her time to 
this task.
The HMA Management Group (MG) held  meetings 
in 007 (mainly by teleconferences) which the 
Permanent Secretariat (PS) also attended and 
supported with agenda setting and minutes. The  
PS also held meetings on a regular basis between 
the MG meetings. The Permanent Secretariat also 
attended the four HMA meetings during the German 
and Portuguese Presidencies.
Among the many issues discussed by the HMA MG 
and PS at their meetings and which were presented 
to the HMA for discussion were:
n Product testing
n Resource planning for the network
n Availability of medicines
n Development of the HMA intranet
n Rules of Procedure for website editors
n Best Practice Guide updates
n Action Plan for the Continuous Development of the 
HMA Co-operation arsing from Strategic Day :
l Redrafting the HMA mission/vision statement;
l Restructure of the HMA Working Groups;
l Revision of the mandates and rules  
of procedure for Working Groups;
l Developed an induction package for  
all heads joining the network;
l Revision of the rules of procedure for the 
management group and permanent secretariat;
l Survey of all activities and responsibilities  
of each national Competent Authorities;
l Database of the skills within the network.
The IMB’s member of the Permanent Secretariat 
continues to act as the main contact point for the 
network and stakeholders worldwide.
The Permanent Secretariat continues to provide 
quality assurance for HMA minutes and documents.
dr. Mike Morris, Senior Scientific Advisor
dr. Caitríona Fisher, Quality Manager
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BORDERLInE PRODUCT 
CLASSIFICATIOn
The Irish Medicines Board provides a service to 
stakeholders to assist in clarifying which products 
should be categorised as medicinal products and 
medical devices and thereby fall under the remit of 
IMB from a regulatory perspective and to distinguish 
such products from other products which are 
outside the scope of IMB’s remit. Queries routinely 
are received in regard to human medicinal products, 
veterinary medicinal products and medical devices 
and in each of the three areas, relevant personnel 
within the organisation have provided on request,  
an IMB decision as to the status of a given product. 
During 006, this service in each of the three areas 
was standardised and brought together under the 
umbrella of the developing IMB Quality Management 
System QMS and in 007 has been the subject of 
an internal audit.
human Medicines
A classification service is operated for products 
which are on the borderline of human medicines 
and other products such as food supplements, 
cosmetics and medical devices. Requests for 
classification whether external or internal are 
ultimately presented to an internal multi-disciplinary 
human medicines Classification Committee which 
meets once a month. The outcome of the decision 
is conveyed promptly to the enquirers and in turn is 
accompanied by a recommendation for any action 
arising depending upon the circumstances. In the 
event of an appeal to the Classification Committee 
decision, the matter will normally be referred to  
the Management Committee which may request  
the advice of the Advisory Committee for Human 
Medicines for arbitration. Full details of the 
procedure can be found in the guideline ‘Definition 
of a Medicinal Product’ which can be found on the 
IMB website. This was revised in 007 following 
the implementation of the new legislation.
The IMB Classification Committee (human medicines) 
met  times in 007 and considered a total of 67 
new products. In addition, there were  products 
revisited from pre-007. The Committee consists  
of appropriately experienced IMB staff from  
Human Medicines, Compliance and Medical Device 
departments and is chaired by Dr. J.M. Morris, 
Senior Scientific Advisor.
During 007, the majority of the applications were 
external applications (0); and most of the internal 
applications emanated from the Compliance 
Department.
The Committee continues to work closely with 
representatives of the IMB Compliance Department 
– Market Compliance Section, which is represented 
on the Committee, and Enforcement Section. 
Externally, there is also a very close working 
relationship with Food Safety Authority of Ireland 
and a number of referrals were made in either 
direction during the course of 007.
The Committee also engaged in regular dialogue 
with the Department of Health and Children and 
with the Advertising Standards Authority in regard 
to slimming products.
huMaN MEdICINES –  
SOurCE OF CLaSSIFICaTION QuErIES
External Applications 63%
Internal Applications 25%
For Information 1%
Revisited 11%
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veterinary Medicinal Products
A classification service for veterinary medicinal 
products operates in a manner similar to that for 
human medicines and a decision is normally granted 
from within the Veterinary Medicines department  
of the IMB and conveyed promptly to the enquirers. 
In cases of appeal of the decision making process, 
the matter is normally referred to the Management 
Committee which may request the advice of the 
Advisory Committee for Veterinary Medicines.
A total of 8 classification queries were processed 
by the Department in 007.
Medical devices
A classification service for medical devices  
operates in a manner similar to that for human 
medicines and a decision is normally granted from 
within the Medical Devices department of the IMB 
and conveyed promptly to the enquirers. In the 
event of a borderline issue the product may be 
referred to the IMB Classification Committee  
for an opinion. Classification issues may also be 
referred to the Advisory Committee on Medical 
Devices for advice and/or to the European 
Competent Authority enquiry system for opinion. 
Full details of the procedure can be found in the 
guidance note 5; ‘Classification of Medical Devices’.
In 007, 50 classification queries were received, 
54% of which originated from other Competent 
Authorities in Europe. A number of these queries 
require further discussion at the Medical Devices 
Expert Group (MDEG) Classification Borderline 
Working Group. Two requests originated from the 
IMB Classification Committee (Human Medicines). 
There were ten external requests, six of which  
were subject to the classification review fee. The 
remaining queries were from within the Medical 
Devices Department, mainly arising from the post-
market surveillance area. A total of six classification 
queries that were borderline products were referred 
to the IMB Classification Committee.
SOurCE OF MEdICaL dEvICE CLaSSIFICaTION 
QuErIES
Competent Authority Query 54%
Medical Device Department 22%
Classification Committee 4%
External 20%
QUALITy MAnAGEMEnT
Implementation of the IMB-wide quality 
management system
During the year, further progress was made in  
the implementation of the organisation’s quality 
system. Some 9 new documents and 65 
requests for revision of documents were approved; 
six documents were withdrawn. At the end of  
the year, 87 document approvals were still  
in progress. Documents which are for external 
stakeholder use are posted on the IMB’s website, 
while those for internal use are posted on an 
intranet for staff.
The graph on the next page shows the cumulative 
number of document control requests, document 
approvals and outstanding documents since system 
implementation began. At the end of the year,  
there were 7 documents approved within the 
organisation’s system.
Little migration of current department quality 
systems to the organisation’s system occurred 
during 007. This was due in part to business 
process re-engineering in some departments and  
to the upcoming external audit of the Compliance 
Department under the EU’s Joint Audit Programme. 
It is anticipated that migration of documents will 
start again in mid-008.
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At the end of the year, 5% of the estimated  
total implementation has been achieved or was in 
progress, as shown in the graph below. Progress  
in each system is shown below by system.
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Internal audit of the quality system began during 
007. Seven audits of the IMB’s system were 
conducted in a range of areas using internal auditors 
drawn from the departments as well as QMS staff. 
The objective of the audits was to determine 
conformance to procedures, though opportunities 
for improvement were also identified. At year-end, 
corrective action plans were approved and actions 
had been taken for all but one audit. Staff in the 
areas being audited reported that the audits were 
constructive and contributed to quality assurance 
and improvement of their procedures.
Updates on the quality system were communicated 
to staff on an ongoing basis and induction training 
was carried out for all new staff.
In March, the QMS section carried out an internal 
customer survey, with responses received from 
about one-third of staff. A very high proportion 
(96%) commented that QMS documents are of 
value to them in their work: to provide instructions, 
assist in training, ensure consistency, and to identify 
areas for improvement. Overall satisfaction with the 
service of the QMS section was 4. on a scale of  
 (very dissatisfied) to 5 (very satisfied). The results 
of the survey showed a very positive attitude to 
QMS among those who responded.
Benchmarking of European Medicines 
agencies
The IMB co-chaired and participated in the Heads  
of Medicines agencies Steering Group for the 
second cycle of Benchmarking of European 
medicines agencies (BEMA). While the method  
of benchmarking is primarily unchanged from  
the first cycle carried out from 004 to 006, the 
questionnaire for assessment was substantially 
revised during the year. Indicators were re-written  
to improve clarity and understanding, and the 
assessors’ report format modified so as to highlight 
strengths/best practices for the benefit of the 
network and the visited agency. In order to improve 
the consistency of the process, guidance for each 
indicator has been agreed and documented; criteria  
for lead assessors and assessors have been 
defined; and significant training provided. The 
second cycle is due to commence in 008 and  
run over a three-year period.
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FINaNCE aNd COrPOraTE aFFaIrS
The Finance and Corporate Affairs Department 
delivers a number of key services areas to the 
organisation. These include:
n Management and safeguarding the finances  
of the IMB.
n Developing and managing the human resource 
needs of the organisation.
n Providing secretarial support to the Board and 
Committees and ensuring adherence to best 
practice in the area of corporate governance.
n Managing the building and accommodation 
requirements of the IMB
n Providing infrastructure requirements for the 
staff and visitors from cleaning, reception, 
canteen, travel service through to library services.
n Managing the Freedom of Information obligations
n Managing the legal issues for the IMB.
The year 007 was another challenging and busy 
year for the department and some of the highlights 
are outlined below.
FInAnCE
As outlined in the Financial Statements, the IMB 
experienced another year of financial growth. The 
finance section continued to successfully manage 
the high volumes of work while maintaining high 
standards of internal control. To further increase 
efficiency and control a new purchase order system 
and fixed assed register were implemented during 
the year. In 007 internal auditors reviewed creditors, 
travel and subsistence and corporate governance 
with a satisfactory outcome. They also reviewed 
their recommendations from their audit in 005 of 
payroll and human resources. All procedures were 
carried out using standard operating procedures 
under the IMB quality management system which 
has added real value to the operation of the 
department.
Ms. rita Purcell, Director of Finance and Corporate Affairs
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HUMAn RESOURCES
The Human Resources section had a significant  
year in the area of recruitment, training and the  
roll-out of the HR strategic aims throughout the 
IMB. The IMB has continued to develop best 
practice in all areas of human resources and during 
007 completed the roll-out of QMS in the unit.  
The time and attendance system was upgraded to 
provide enhanced reporting facilities and transfer  
to electronic recording of annual leave. The IMB has 
identified staff training and development as a key 
building block in the organisation’s commitment to 
excellence and has continued to invest significantly 
in the area of providing support for the implementation 
of change programmes across the organisation.
recruitment
Overall there were 4 external recruitment competitions 
in addition to 7 internal promotional opportunities 
resulting in the appointment of 9 additional technical 
personnel across a number of departments. ( female 
and 6 male).
TraININg
Courses 2007
No of 
Courses
No of 
training 
days
External courses/seminars 00 497.5
Internal – general  5.0
Internal – technical  05.5
Internal IT 56 7.5
% of employees 
supported in further 
education programmes 8.9%
2007
Number of 
FOI requests 
received
granted/Part 
granted refused
Withdrawn/
handled 
outside FOI act
Internal 
reviews
appeals to the 
Information 
Commissioner
9 0 4 5  
CORPORATE SERVICES
007 was a busy year for corporate services as the 
increases in operations and staff outlined in all the other 
departments increase the level of services provided. 
In December 007 the IMB hosted the International 
Summit for the Heads of Regulatory Agencies which 
was a considerable success. The hospitality and 
organisation of the conference was organised by 
Corporate Services and the dinner in Farmleigh provided 
a memorable night for the foreign delegates. In addition 
to the International Summit the section also 
facilitated four other conferences in 007.
In the area of corporate governance revised terms 
of reference for all the committees and Board were 
completed and particular emphasis was given to  
the role of corporate governance in the organisation. 
Training in best practice for corporate governance 
was provided to the Board members.
There was a large number of Freedom of Information 
Act request in 007. The IMB received 5 non personal 
requests and 4 personal requests for information. 
The outcome of these requests is outlined below:
Buildings
In 005 the Board approved the complete renovation 
of Kevin O’Malley House following the purchase of 
the building in December 004. This project was 
commenced in late 006 and was successfully 
completed in December 007. This was a very 
challenging project as every floor was completely 
stripped and fully renovated while the building was 
kept live, while at the same time managing the 
expectations of both our internal and external 
stakeholders.
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BOARD MEMBERS AnD OTHER InFORMATIOn
Board Members: Mr. Pat O’Mahony (Chairman) 
Mr. Pat Brangan 
Dr. Brendan Buckley 
Mr. Wilfrid Higgins 
Ms. Ingrid Hook 
Mr. Brendan McLoughlin 
Ms. Cicely Roche 
Ms. Maureen Windle
 The new Board was appointed by the  
Minister for Health & Children for a term  
of 5 years from st January 006.
Bankers: Allied Irish Bank 
Lower Baggot Street 
Dublin 
 Bank of Ireland Corporate 
Lower Baggot Street 
Dublin 
Solicitors: Eugene F. Collins 
Temple Chambers 
, Burlington Road 
Dublin 4
head Office: Kevin O’Malley House 
Earlsfort Centre 
Earlsfort Terrace 
Dublin 
auditor: Comptroller and Auditor General 
Dublin Castle 
Dublin 
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CORPORATE GOVERnAnCE
The Irish Medicines Board (the IMB) was established 
under the terms of the Irish Medicines Board Act, 
995, and is governed by a Board which was 
appointed by the Minister for Health & Children.  
The Board of the IMB (the Board) consists of a 
chairman and seven unremunerated non executive 
members.
The IMB is committed to the highest standards of 
Corporate Governance and has implemented the 
Department of Finance “Code of Practice for the 
Governance of State Bodies”. This Code of Practice, 
which was issued to the Irish Medicines Board in 
January 00, incorporates many of the principles 
under which the IMB operates, taking account of 
the size and legal nature of the organisation. The 
IMB has in place an extensive code of conduct for  
all staff, committees and Board members. The IMB 
applies the highest standards of disclosure and 
transparency in respect of interests held by staff, 
committees and Board members.
audit Committee
The IMB has an audit committee comprising two 
Board members, which met on three occasions 
during 007. This committee is responsible for 
reviewing internal control matters, together with  
any other issues raised by the external auditors, the 
Board or management. The external auditor meets 
annually with the committee to brief them on the 
outcome of the external audit. In 005 the IMB 
appointed Crowleys DFK as internal auditor to the 
Board under a three-year contract. During 007 the 
internal auditors reviewed the areas of creditors, 
payroll/HR and expenses and reported their findings 
to the audit committee. The audit committee has 
also been involved with the review of the quality 
systems as described below.
Quality Systems
During 007, the finance section of the IMB 
continued the process of implementing and 
reviewing standard operating procedures (SOPs) 
under the quality management system. This process 
involved a critical review and analysis of internal 
controls and processes throughout the section  
with particular emphasis on risk management.  
This system now underpins the internal control 
environment and feeds into the internal audit 
process and ultimately into the audit committee.
remuneration Policy – Board Members  
and Executive directors
Remuneration and travel expenses paid to Board 
members are disclosed in note 7 to the financial 
statements. The Chairman receives remuneration  
as directed by the Minister for Health and Children 
in accordance with the Irish Medicines Board Act, 
995. Other Board members receive travel expenses 
in accordance with circulars issued by the 
Department of Health and Children. The Chief 
Executive is remunerated in accordance with 
guidelines issued from government and other 
Executive Directors are paid in accordance with 
Department of Health and Children pay scales.
remuneration Committee
The IMB has established a remuneration committee 
as a sub-committee of the Board to review the 
remuneration of the Chief Executive in accordance 
with guidelines issued by the Department of 
Finance and the Department of Health & Children. 
The Chief Executive’s remuneration is disclosed net 
of superannuation contributions in note 8 to the 
Financial Statements.
Internal Control
The Board is responsible for the IMB’s systems  
of internal control. Such systems can only provide 
reasonable and not absolute assurance against 
material misstatement or loss. The systems of internal 
controls in use in the Irish Medicines Board are 
described more fully in the Chairman’s report on 
page 5.
going Concern
The Board has a reasonable expectation, at the time 
of approving the financial statements, that the IMB 
has adequate resources to continue its operations for 
the foreseeable future. For this reason, it continues 
to adopt the going concern basis in preparing the 
financial statements.
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REPORT OF THE CHAIRMAn OF THE IRISH MEDICInES BOARD
regarding the assessment of internal financial controls of a State body for the year ended 31st December 2007
. I, as Chairman, acknowledge that the Board is 
responsible for the body’s system of internal 
financial control.
. The IMB system of internal control can provide 
only reasonable and not absolute assurance 
against material error, misstatement or loss.
. The Board confirms that there is an ongoing 
process for identifying, evaluating and  
managing the significant risks faced by the  
IMB. This process is regularly reviewed by  
the Board via the report of the Chief Executive.
 Management are responsible for the identification 
and evaluation of significant risks applicable to 
their areas of business together with the design 
and operation of suitable internal controls. These 
risks are assessed on a continuing basis and 
may be associated with a variety of internal or 
external sources including control breakdowns, 
disruption in information systems, natural 
catastrophe and regulatory requirements.
 Management reports fortnightly on operational 
issues and risks and how they are managed to 
the Management Committee. The Management 
Committee’s role in this regard is to review on 
behalf of the Board the key risks inherent in  
the affairs of the IMB and the system of actions 
necessary to manage such risks and to present 
their findings on significant matters via the  
Chief Executive to the Board.
 The Chief Executive reports to the Board  
on behalf of the executive management on 
significant changes in the work of the IMB  
and on the external environment, which affects 
significant risks. The Director of Finance and 
Corporate Affairs provides the Board with 
monthly financial information, which includes 
key performance indicators. Where areas for 
improvement in the system are identified the 
Board considers the recommendations made  
by the Management Committee.
 An appropriate control framework is in place 
with clearly defined matters which are reserved 
for Board approval only or, as delegated by  
the Board, for appropriate Executive approval. 
The Board has delegated the day-to-day 
management of the IMB and established 
appropriate limits for expenditure authorisation  
to the Executive. The Chief Executive is 
responsible for implementation of internal 
controls, including internal financial control.
 The system of internal financial control is 
monitored in general by the processes outlined 
above. In addition, the Audit Committee of the 
Board reviews specific areas of internal control  
as part of their terms of reference.
4. The Audit Committee of the Board have 
satisfactorily reviewed the effectiveness of  
the system of internal control on behalf of the 
Board. The Audit Committee of the Board 
carried out a formal review of these systems in 
respect of 007 at its meeting on 6th June 008.
Mr. Pat O’Mahony 
Chairman to the Board
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STATEMEnT OF BOARD MEMBERS’ RESPOnSIBILITIES
The Board is required by the Irish Medicines Board 
Act, 995 to prepare financial statements for each 
financial year which give a true and fair view of the 
state of affairs of the Irish Medicines Board and of 
its surplus or deficit for that period.
In preparing those statements the Board is required 
to:
n select suitable accounting policies and apply 
them consistently
n make judgements and estimates that are 
reasonable and prudent
n disclose and explain any material departures 
from applicable accounting standards, and
n prepare the financial statements on a going 
concern basis unless it is inappropriate to 
presume that the Irish Medicines Board will 
continue in existence.
The Board is responsible for keeping proper 
accounting records which disclose with reasonable 
accuracy at any time the financial position of  
the Irish Medicines Board and which enable it  
to ensure that the financial statements comply  
with the IMB Act and with accounting standards 
generally accepted in Ireland. It is also responsible 
for safeguarding the assets of the Irish Medicines 
Board and hence for taking reasonable steps for  
the prevention and detection of fraud and other 
irregularities.
On behalf of the Board
Chairman
Board Member
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REPORT OF THE COMPTROLLER AnD AUDITOR GEnERAL
for presentation to the Houses of the Oireachtas
I have audited the financial statements of the Irish 
Medicines Board for the year ended  December 
007 under Section 8 of the Irish Medicines Board 
Act, 995.
The financial statements, which have been  
prepared under the accounting policies set out 
therein, comprise the Accounting Policies, the 
Statement of Income and Expenditure, the 
Statement of Total Recognised Gains and Losses, 
the Balance Sheet, the Cash Flow Statement and 
the related notes.
respective responsibilities of the Board 
and the Comptroller and auditor general
The Irish Medicines Board is responsible for 
preparing the financial statements in accordance 
with the Irish Medicines Board Act, 995, and for 
ensuring the regularity of transactions. The Board 
prepares the financial statements in accordance 
with Generally Accepted Accounting Practice in 
Ireland as modified by the directions of the Minister 
for Health and Children in relation to accounting for 
superannuation costs. The accounting responsibilities 
of the Board Members are set out in the Statement 
of Board Members’ Responsibilities.
My responsibility is to audit the financial statements 
in accordance with relevant legal and regulatory 
requirements and International Standards on 
Auditing (UK and Ireland).
I report my opinion as to whether the financial 
statements give a true and fair view, in accordance 
with Generally Accepted Accounting Practice in 
Ireland. I also report whether in my opinion proper 
books of account have been kept. In addition,  
I state whether the financial statements are in 
agreement with the books of account.
I report any material instance where moneys  
have not been applied for the purposes intended  
or where the transactions do not conform to the 
authorities governing them.
I also report if I have not obtained all the information 
and explanations necessary for the purposes of my 
audit.
I review whether the Statement on Internal Financial 
Control reflects the Board’s compliance with the 
Code of Practice for the Governance of State Bodies 
and report any material instance where it does  
not do so, or if the statement is misleading or 
inconsistent with other information of which I am 
aware from my audit of the financial statements.  
I am not required to consider whether the Statement 
on Internal Financial Control covers all financial  
risks and controls, or to form an opinion on the 
effectiveness of the risk and control procedures.
I read other information contained in the Annual 
Report, and consider whether it is consistent with 
the audited financial statements. I consider the 
implications for my report if I become aware of any 
apparent misstatements or material inconsistencies 
with the financial statements.
Basis of audit Opinion
In the exercise of my function as Comptroller  
and Auditor General, I conducted my audit of the 
financial statements in accordance with International 
Standards on Auditing (UK and Ireland) issued by  
the Auditing Practices Board and by reference  
to the special considerations which attach to  
State bodies in relation to their management  
and operation. An audit includes examination,  
on a test basis, of evidence relevant to the amounts 
and disclosures and regularity of the financial 
transactions included in the financial statements.  
It also includes an assessment of the significant 
estimates and judgments made in the preparation  
of the financial statements, and of whether the 
accounting policies are appropriate to the Board’s 
circumstances, consistently applied and adequately 
disclosed.
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I planned and performed my audit so as to obtain all 
the information and explanations that I considered 
necessary in order to provide me with sufficient 
evidence to give reasonable assurance that the 
financial statements are free from material 
misstatement, whether caused by fraud or other 
irregularity or error. In forming my opinion I also 
evaluated the overall adequacy of the presentation  
of information in the financial statements.
Opinion
As explained in the Accounting Policies, the  
Board recognises the costs of superannuation 
entitlements only as they become payable. This 
policy does not comply with Financial Reporting 
Standard 7 which requires such costs to be 
recognised in the year the entitlements are earned. 
While non-compliance with Financial Reporting 
Standard 7 does not impact on the overall financial 
performance or position of the Board as disclosed in 
the financial statements, in my opinion compliance 
is necessary for a proper understanding of the costs 
of providing the superannuation benefits earned by 
employees during the year and of the value of the 
benefits that the Board has committed to providing  
in respect of service up to the year end.
Except for the non-recognition of the Board’s 
superannuation costs and liabilities, which is not  
in accordance with Financial Reporting Standard 7, 
the financial statements give a true and fair view,  
in accordance with Generally Accepted Accounting 
Principles in Ireland, of the state of the Board’s 
affairs at  December 007 and of its income  
and expenditure for the year then ended.
In my opinion, proper books of account have been 
kept by the Board. The financial statements are in 
agreement with the books of account.
Gerard Smyth 
For and on behalf of the  
Comptroller and Auditor General
 September 008
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ACCOUnTInG POLICIES
historical Cost Convention
The Financial Statements are prepared in 
accordance with generally accepted accounting 
principles under the historical cost convention and 
comply with the financial reporting standards of the 
Accounting Standards Board, with the exception of 
superannuation – see note below.
Income recognition
Income is recognised in the financial statements  
on the following basis:
n In the case of applications for product 
authorisations (new applications, variations to 
existing authorisations, or transfers) and clinical 
trial applications, income is recognised in the 
financial statements when a valid application 
form is received.
n In the case of wholesale and manufacturing 
licences and maintenance of product 
authorisations, fees are payable annually and a 
full year’s income is accrued in each financial year.
Expenditure recognition
Expenditure is recognised in the financial 
statements on an accruals basis as it is incurred.
reporting Currency and Currency Translation
The financial statements are prepared in euros.
Transactions in currencies other than euro are 
recorded at the rates ruling at the date of the 
transactions or at a contracted date. Monetary 
assets and liabilities are translated into euro at  
the balance sheet date or at a contracted date. 
Exchange differences are dealt with in the income 
and expenditure account.
Tangible assets
Tangible assets excluding Premises
Tangible assets excluding premises are stated at 
cost less accumulated depreciation. Depreciation  
is calculated in order to write off the cost of tangible 
assets to their estimated residual values over their 
estimated useful lives by equal annual instalments.
The estimated useful lives of tangible assets by 
reference to which depreciation has been calculated 
are as follows:
Leasehold Property: unexpired portion  
 of the lease
Fixtures and Fittings: 5 years
Computer Equipment: 3 years
Improvements to Premises: 10 years
Premises
The IMB purchased its premises at Kevin O’Malley 
House, Earlsfort Centre, Earlsfort Terrace, Dublin  
on nd December 004. The value capitalised was 
equal to the purchase price plus those costs directly 
attributable to bringing the asset into use.
no depreciation has been calculated on the value  
of premises, as the remaining useful economic  
life is estimated to be greater than 50 years. An 
impairment review was carried out in April 008  
and the value of premises was considered to be 
appropriate.
Taxation
The Irish Medicines Board is exempt from liability  
to Corporation Tax under Section  of the Finance 
Act, 994.
debtors
Known bad debts are written off and specific 
provision is made for any amount the collection  
of which is considered doubtful.
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Superannuation
The superannuation scheme operated by the Irish 
Medicines Board is in accordance with the Local 
Government (Superannuation Revision) (Consolidation) 
Scheme, 986. It is an unfunded statutory scheme 
and benefits are met from current income as they arise.
The charge to salaries and wages is stated gross  
of superannuation deductions of €5,844 (006 - 
€594,450). The surplus for the year on page 59 is 
then shown both before and after superannuation 
transactions for the year. The income and 
expenditure reserve on the balance sheet is split 
between retained reserves and superannuation 
reserves in note .
By direction of the Minister for Health & Children, 
the provisions of FRS 7 are not being complied with.
Provisions
It is the policy of the IMB to make adequate 
provision for any litigation that may arise. Due to  
the confidential nature of such transactions, it is not 
the policy of the IMB to disclose such information.
Library
no value has been placed on the books, audio-visual 
resources and electronic databases in the library. 
Expenditure on these items is written off in the  
year in which it is incurred.
Leases
All leases are treated as operating leases and the 
rentals thereunder are charged to the Income and 
Expenditure account on a straight line basis over  
the lease period.
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STATEMEnT OF InCOME AnD EXPEnDITURE
for the year ended 31st December 2007
Note 2007 2006
€ €
Fee Income 2 17,239,949 5,965,9
Other Income 3 5,073,029 4,54,50
22,312,978 0,0,4
Salaries and Wages 4 13,239,398 ,985,846
Other Operating Costs 5 5,951,791 5,99,854
Depreciation 1 1,247,081 ,086,8
20,438,270 8,47,08
Surplus for the year before write back  
of Superannuation contributions 1,874,708 ,648,48
Staff Superannuation Contributions 521,844 594,450
Surplus for the year 2,396,552 ,4,798
Balance brought forward 10,278,395 8,05,597
Balance carried forward 12,674,947 0,78,95
All income and the surplus for the year arises from continuing activities.
Chairman
Board Member
The accounting policies on pages 57 to 58 and the notes on pages 6 to 69 form part of the financial statements.
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STATEMEnT OF TOTAL RECOGnISED GAInS AnD LOSSES
for the year ended 31st December 2007
2007 2006
€ €
Retained Surplus For The year 2,396,552 ,4,798
Unrealised Gains For The year – –
Total Recognised Gains 2,396,552 ,4,798
The accounting policies on pages 57 to 58 and the notes on pages 6 to 69 form part of the financial statements.
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BALAnCE SHEET
as at 31st December 2007
Note 2007 2006
€ €
Tangible Assets 1 24,657,277 ,50,8
Current Assets
Debtors and Prepayments 6 1,703,351 ,86,8
Stock of Stationery 4,707 5,040
Cash at Bank and in Hand 12 1,711,782 59,457
Short Term Deposits 2,153,665 ,6,87
5,573,505 5,48,
Creditors – Amounts falling due within one year
Creditors and Accruals 7 4,975,835 4,579,945
Mortgage 13 340,000 40,000
5,315,835 4,99,945
Net Current Assets 257,670 8,67
Long Term Liabilities
Mortgage 13 12,240,000 ,580,000
TOTAL NET ASSETS 12,674,947 0,78,95
Financed by
Income and Expenditure Reserve 11 12,674,947 0,78,95
12,674,947 0,78,95
Chairman
Board Member
 
The accounting policies on pages 57 to 58 and the notes on pages 6 to 69 form part of the financial statements.
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CASH FLOW STATEMEnT
for the year ended 31st December 2007
Note 2007 2006
€ €
Reconciliation of surplus to net cash inflow  
from operating activities
Surplus for year 2,396,552 ,4,798
Depreciation Charge 1,247,081 ,086,8
(Increase)/Decrease in Debtors (317,023) (05,56)
(Increase)/Decrease in Stocks 333 (59)
Increase/(Decrease) in Creditors – amounts falling 
due within one year 395,890 ,5,7
Deposit Interest (79,717) (5,580)
Bank Interest and Charges 540,444 57,40
Loss/(Gain) on Disposal of Fixed Assets 44,092 ,898
net Cash Inflow from Operating Activities 4,227,652 5,08,894
Cash Flow Statement
Net Cash Inflow from Operating Activities 4,227,652 5,08,894
Return on Investments and Servicing of Finance 8 (460,727) (56,850)
Capital Expenditure 8 (3,418,322) (,476,7)
Management of Liquid Resources 8 1,109,722 (,98,0)
Financing 8 (340,000) (,90,000)
Increase/(Decrease) in Cash 1,118,325 (,,6)
Reconciliation of net cash flow  
to movement in net debt
Increase/(Decrease) In Cash 1,118,325 (,,6)
Increase/(Decrease) In Short Term Deposits (1,109,722) ,98,0
(Increase)/Decrease In Long Term Finance 340,000 ,90,000
Change In net Debt 348,603 ,095,77
net Debt at start of year (9,063,156) (,58,87)
net Debt at end of year 9 (8,714,553) (9,06,56)
The accounting policies on pages 57 to 58 and the notes on pages 6 to 69 form part of the financial statements.
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nOTES TO THE FInAnCIAL STATEMEnTS
for the year ended 31st December 2007
1 Tangible assets
Fixtures 
and 
Fittings
Computer 
Equipment
Leasehold 
Improve- 
ments
Improve-
ments to 
Premises Premises Total
€ € € € € €
Cost
Balance as at  
st January 007 688,564 5,887,4 50,445 68, 0,549,66 8,45,79
Additions  
for the year 95,59 9,098 – ,55,974 954,690 ,48,54
Disposals  
for the year (400,976) (,,60) – – – (,5,586)
As at st 
December 007 68,80 5,667,99 50,445 ,774,087 ,50,856 0,,487
Depreciation
Balance as at  
st January 007 58,94 4,989,95 99, 87,59 – 5,75,59
Charge for  
the year ,896 895,5 50,45 77,409 – ,47,08
Disposals  
for the year (70,988) (,7,474) – – – (,488,46)
As at st 
December 007 9,8 4,767,97 49,478 64,98 – 5,474,0
Net Book value  
at 31st December 
2007 9,48 899,947 5,967 ,509,59 ,50,856 4,657,77
Net Book value at  
1st January 2007 49,640 897,56 40, 50,594 0,549,66 ,50,8
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2 Income
2007 2006
€ €
Fee Income
Clinical Trials 118,081 4,6
Human Medicine – national Fees 6,090,886 6,88,4
Human Medicine – European Fees 6,025,588 4,60,466
Veterinary Medicine – national Fees 1,150,323 ,8,4
Veterinary Medicine – European Fees 854,874 478,96
Compliance Department 2,853,490 ,70,4
Medical Devices 146,707 ,59
17,239,949 5,965,9
Other Income (Note 3) 5,073,029 4,54,50
Total Income 22,312,978 0,0,4
 Certain fees, totalling €,459,49, are required by law to be disposed of in accordance with the 
directions of the Minister for Finance.
3 Other Income
2007 2006
€ €
Department of Health & Children Funding 4,924,000 4,05,000
IT Income 13,000 ,000
Conference Fee Income 88,402 98,88
Deposit Interest 79,717 5,580
(Loss)/Gain on Disposal of Fixed Assets (44,092) (,898)
Miscellaneous 12,002 5,000
5,073,029 4,54,50
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4 Salaries and Wages
2007 2006
€ €
Salaries and Wages 12,113,971 0,99,76
Social Welfare Costs 1,125,427 994,0
13,239,398 ,985,846
 The average number of staff employed during the year was 4 (006 - 8).
 Staff employed at st December 007 can be analysed across the following departments:
2007 2006
Medical Technical 15 5
Pharmaceutical Technical 28 5
Veterinary Technical 11 0
Compliance Technical 18 
Medical Devices Technical 14 0
Enforcement Technical 8 8
Scientific Technical 1 
Blood Directive Technical 5 5
Controlled Drugs Technical 2 
Tissues Technical 2 –
Administrative and Operational Staff 124 9
Pensioners 10 8
238 5
5 Operating Costs
€ €
Accommodation Costs 1,096,121 ,005,54
Travel, Representation and Training 1,153,890 87,05
Bank Charges and Interest 540,444 57,40
Legal & Professional Fees 591,150 ,07,06
Stationery, Publications and Postage 396,123 06,77
Other Operating Costs 2,174,063 ,57,05
5,951,791 5,99,854
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6 debtors (all due within one year)
2007 2006
€ €
Trade Debtors 1,340,493 ,,677
Prepayments 266,401 60,
Other Debtors 96,457 94,8
1,703,351 ,86,8
7 Creditors (amounts falling due within one year)
2007 2006
€ €
Trade Creditors 702,718 555,876
Accruals 3,842,994 ,675,890
Revenue 430,123 48,79
4,975,835 4,579,945
8 gross Cash Flows
2007 2006
€ €
Returns on Investment and Servicing of Finance:
Deposit Interest 79,717 5,580
Bank Interest and Charges (540,444) (57,40)
(460,727) (56,850)
Capital Expenditure
Payments to acquire Tangible Fixed Assets (3,418,354) (,476,807)
Receipts from sales of Tangible Fixed Assets 32 480
(3,418,322) (,476,7)
Management of Liquid Resources
(Increase)/Decrease in Short Term Deposits 1,109,722 (,98,0)
1,109,722 (,98,0)
Financing
Increase/(Decrease) in Long Term Finance (340,000) (,90,000)
(340,000) (,90,000)
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9 analysis of Changes in Net debt
as at 
01/01/2007 Cashflow
as at 
31/12/2007
Cash at Bank and in Hand 593,457 ,8,5 ,7,78
Short Term Deposits 3,263,387 (,09,7) ,5,665
Debt Due Within One year (340,000) – (40,000)
Debt Due After One year (12,580,000) 40,000 (,40,000)
(9,063,156) 48,60 (8,74,55)
10 administration Expenses
2007 2006
Surplus for the year was calculated having charged:
Auditor’s Remuneration 18,500 5,800
11 Income and Expenditure reserves
 The Income and Expenditure Reserve disclosed in the Balance Sheet on page 6 comprises the 
following:
2007 2006
Retained Reserves 9,486,806 7,6,098
Staff Superannuation Contributions 3,188,141 ,666,97
12,674,947 0,78,95
12 Cash and Bank Balances
2007 2006
€ €
Current Account Balances 9,098 9,8
Deposit Account Balances 1,700,000 500,000
Cash on Hand 2,684 ,76
1,711,782 59,457
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13 Long Term Liabilities
 Mortgage
 On nd December 004 the Board purchased its premises at Kevin O’Malley House, Earlsfort 
Centre, Earlsfort Terrace, Dublin . The purchase was financed by way of a mortgage, secured on the 
premises, of €0,400,000 over 0 years from Bank of Ireland Corporate Lending.
 The Irish Medicines Board is committed to making the following capital repayments on its mortgage:
2007 2006
€ €
n within one year 340,000 40,000
n between one and five years 1,360,000 ,60,000
n after five years 10,880,000 ,0,000
12,580,000 ,90,000
14 Interest rate Exposure
 The IMB have taken all necessary steps to minimise its interest rate exposure by fixing /s of the 
borrowings for a period of 0 years. The balance of the borrowings are fully offset by cash reserves.  
For 008 it is estimated that the net borrowings for which an interest rate exposure may arise is €0.
15 Financial Commitments
2007 2006
€ €
Operating Leases
Amounts payable during the next twelve
months in respect of leases which expire
n within one year – –
n between one and five years – –
n after five years (in respect of Alexandra House) 236,000 6,000
236,000 6,000
 The operating lease amount includes an annual commitment of €6,000 in respect of the Board’s 
premises at Alexandra House, Earlsfort Centre, Earlsfort Terrace, Dublin . As shown in note  
above, the IMB purchased Kevin O’Malley House on nd December 004, which is why no further 
lease obligations exist in respect of that premises.
 On nd December 004 the IMB signed a leasehold interest with 7 years remaining in respect  
of the 5th floor, Alexandra House, Earlsfort Centre, Dublin .
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16 Capital Commitments
2007 2006
€ €
Contracted For (Contract Signed) 110,000 80,000
not Contracted For 65,000 00,000
175,000 480,000
17 Board remuneration
2007 2006
€ €
Chairman’s Salary 26,087 5,8
Board Members’ Travel Expenses 8,645 9,788
34,732 5,60
18 Staff remuneration
2007 2006
€ €
Chief Executive’s Remuneration 157,747 5,45
(Stated net of Superannuation Contributions)
157,747 5,45
19 related Party Transactions
 There have been no transactions with related parties which require disclosure under Financial 
Reporting Standard 8.
20 Prompt Payment Of accounts
 The Irish Medicines Board (IMB) confirms that it is complying with EU law in relation to prompt 
payments of account.
21 Exchange rates
 The exchange rates used in preparing these financial statements were as follows:
 007 € = STG £0.75 
006 € = STG £0.675
22 approval of Financial Statements
 The financial statements were approved by the Board on 6th June 008.
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APPENDIX I :  MAnAGEMEnT COMMITTEE MEMBERS  
AnD COMMITTEES
Management Committee
Mr. Pat O’Mahony – Chief Executive 
Dr. J.Gabriel Beechinor –  
Director of Veterinary Medicines 
Dr. Joan Gilvarry – Director of Human Medicines 
Mr. John Lynch – Director of Compliance 
Ms. Suzanne McDonald – Director of Information 
Technology and Change Management 
Dr. J. Michael Morris – Senior Scientific Advisor 
Ms. Ann O’Connor – Medical Devices Director 
Ms. Rita Purcell – Director of Finance and  
Corporate Affairs
advisory Committee for human Medicines
Dr. Brendan Buckley – Chairman 
Dr. Mary Horgan 
Dr. Kevin Connolly 
Prof. John Kelly 
Dr. Pat Sullivan 
Dr. Brendan Silke 
Prof. Ted Dinan 
Mr. Tom McGuinn 
Ms. Eugenie Canavan 
Dr. Paul Browne 
Dr. Desmond Corrigan 
Dr. Íde Delargy
advisory Committee for veterinary 
Medicines
Mr. Pat Brangan – Chairman 
Mr. Tom McGuinn 
Mr. Rory Breathnach 
Ms. Eugenie Canavan 
Mr. Thomas Barragry 
Dr. Anne Cullinane 
Mr. Joseph Britton 
Mr. Matt Browne 
Mr. Michael Clancy 
Dr. Hamish D. Rodger 
Dr. Donal Sammin
advisory Committee for Medical devices
Mr. Wilfrid J. Higgins – Chairman 
Dr. Geoffrey Chadwick 
Ms. Maureen D’Arcy 
Dr. John Keogh 
Prof. Robert McConnell 
Dr. Brendan Cormack 
Dr. Tim McGloughlin 
Ms. Aideen Murphy 
Dr. John O’Mullane 
Ms. Maebh Smith 
Prof. W. Arthur Tanner 
Prof. Wil van der Putten
Clinical Trial Sub-Committee of advisory 
Committee for human Medicines
Dr. Patrick Sullivan – Chairman 
Dr. Liam. T. Bannan 
Dr. Tom Pierce 
Prof. David Bouchier-Hayes 
Dr. John Taffe 
Dr. Paul Browne 
Dr. Pat Manning 
Prof. Ted Dinan 
Prof. Sidney Lowry 
Dr. Brian Cantwell
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Experts Sub-Committee of the advisory 
Committee for human Medicines
Dr. Brendan Buckley 
Dr. Mary Horgan 
Dr. Brion Sweeney 
Dr. Colin Buckley 
Dr. Íde Delargy 
Dr. Stephen Flint 
Dr. Lorraine Kyne 
Dr. Owen Hensey 
Dr. Owen Carey 
Dr. Kevin Connolly 
Dr. Frank Murray 
Dr. Mary Keogan 
Dr. Kevin Kelleher 
Dr. Linda Fenelon 
Dr. John McCaffrey 
Dr. noreen Dowd 
Dr. Patricia McCormack 
Dr. Stephen Eustace 
Dr. Douglas Veale 
Dr. Joseph Galvin 
Prof. Michael Fitzgerald 
Prof. Brian Shephard 
Dr. Tim Fulcher 
Prof. David Kerins 
Dr. Donal Brosnahan 
Dr. Mark Ledwidge
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APPENDIX I I :  GLOSSARy
ADR: Adverse Drug Reaction
ACMD: Advisory Committee for Medical Devices
ACVM: Advisory Committee for Veterinary 
Medicines
AIMDD: Active Implantable Medical Device Directive
BEMA: Benchmarking of European Medicines 
Agencies
BfARM: German Competent Authority
BWP: Biological Working Party
CETF: Clinical Evaluation Task Force
CHMP: Committee for Human Medicinal Products
CMD(h): Co-ordination Group for Mutual 
Recognition & Decentralised Procedures
COMP: Committee for Orphan Medicinal Products
DCP: Decentralised Procedure
DOHC: Department of Health and Children
EC: European Commission
EHn: European Haemovigilance network
EMEA: European Medicines Agency
EUSTITE: EU Project for Standards and Training for 
the Inspection of Tissue Establishments
EWP: Efficacy Working Party
FDA: Food and Drug Administration
GMD: General Medical Device
GTWP: Gene Therapy Working Party
HMA: Heads of Medicines Agencies
HMPC: Committee on Herbal Medicinal Products
ICSRs: Individual Case Safety Reports
IMB: Irish Medicines Board
IMF: Irish Medicines Formulary
ISOP: International Society  
of Pharmacovigilance
IVDs: In-Vitro Diagnostic
IVDD: In-Vitro Diagnostic Medical Device 
Directive
MAHs: Marketing Authorisation Holders
MDD: Medical Device Directive
MDEG: Medical Devices Expert Group
MEDDEV: Medical Devices
MIA: Manufacturing Importation Authorisation
MR: Mutual Recognition
nHO: national Haemovigilance Office
nSAI: national Standards Authority of Ireland
nSAID: non Steroidal Anti Inflammatory Drug
OMCL: Official Medicines Control Laboratory
PDCO: Paediatric Committee
PEMSAC: Platform of European Market 
Surveillance Authorities in Cosmetics
PhVWP: CHMP Pharmacovigilance Working Party
PSUR: Periodic Safety Update Report
QMS: Quality Management System
QWP: Quality Working Party
RIO: Regulatory Information Online System
SAE: Serious Adverse Event
SAG: Scientific Advisory Groups
SAR: Serious Adverse Reactions
SUSARs: Suspected Unexpected Serious  
Adverse Reactions
SWP: Safety Working Party
VCJD: Variant Creutzfeldt-Jakob Disease
VWP: Vaccine Working Party
WHO: World Health Organisation

Kevin O’Malley House 
Earlsfort Centre 
Earlsfort Terrace 
Dublin 2
Tel: +353 1 676 4971 
Fax: +353 1 676 7836 
Email: imb@imb.ie 
Web: www.imb.ie
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